Watch · 63/100 · medium confidence

CAL-MAINE FOODS INC (CALM) — Council Assessment

🟡 WATCH · Score 63/100 · medium confidence

A fortress-balance-sheet egg producer that looks statistically cheap on peak earnings but is a commodity price-taker at a cyclical trough — cheap on normalized numbers, but not by the margin the headline multiples imply.

As of 2026-06-27. 17 lenses weighed in, 1 abstained. Sources: 6 filings, 15 news, 14 discussion, 1 earnings_call.

360 narrative — news & sentiment digest

CALM — Cal-Maine Foods Q3 FY2026 Briefing

Management Commentary (Earnings Call)

Q3 Results & Tone:
EPS came in at $1.60, down 89.8% YoY (vs. $10.38 prior year), but beat consensus estimates. Revenue fell 53% to $667M. Management framed this as a cyclical trough amid AI-driven supply recovery—not fundamental demand weakness. The tone was methodical and defensive: acknowledge near-term pricing pressure, highlight strategic progress, emphasize long-term value creation over quarterly volatility.

Key Strategic Themes:

Specialty egg mix expansion: Now 50.5% of shell egg sales (Q3) vs. 24.4% prior year; 42.7% YTD vs. 29.2%. Management credits "structurally stronger margins, more stable demand, improved returns on invested capital."
Prepared foods acceleration: 9.5% of net sales vs. 0.8% prior year. Echo Lake Foods (acquired) up 283% in prepared foods sales. Crapini Foods in joint venture also contributing.
Hybrid pricing for conventional eggs: Mix of fixed/cost-plus contracts + some spot exposure. Management claims this "de-risks" downside while capping upside—a strategic tradeoff to stabilize normalized earnings.

Guidance & Forward View:

Prepared foods margins currently depressed in Q3 (trough quarter) due to network optimization & capacity expansion underway; management projects recovery starting Q4-26, trending toward 19–20% baseline margins through FY2027–2028.
Prepared foods capacity to grow >30% over 18–24 months.
No explicit EPS guidance issued; focus on "normalized earnings power" over multi-year horizon.

Capital Allocation (12-month summary through Q3):

~$1.0B deployed: 38% dividends ($384M), 30% acquisitions ($299M including Echo Lake, Creighton Brothers/Crystal Lake), 17% CapEx ($117M, ~35M maintenance), 15% buybacks ($150M).
Cash position: $1.152B (down 17% from prior quarter), virtually debt-free.
Dividend: $0.36/share (variable, tied to earnings).

AI & Market Backdrop: Management acknowledged high-path avian flu still present but "meaningfully lower" impact than 2025. Layer flock up 2.2% YoY; depopulations down 70.6%. Wholesale prices softened; retail adjusting gradually. Demand remains "stable to improving"—retail egg volumes +3% YTD; food service recovering.

Notable Q&A Exchanges:

Specialty pricing stability: ~88% of specialty pricing under fixed/cost-plus contracts; only ~12% tied to volatile California case-free market. Expected to remain "pretty flat."
Conventional hybrid pricing performance: "Performed exactly like designed"—protection for customers on upside, for CALM on downside. Benefited company this quarter amid $2.69–$0.85 price swing in southeast.
Prepared foods baseline: Management clarified 19–20% margins are the target; near-term investments and network reconfig causing temporary drag; expect recovery ramp through 2027–2028, not full recovery by end of 2027.
M&A appetite & liquids: Creighton Brothers/Crystal Lake adds liquid egg capacity near southern echo facilities; seen as enabling tighter vertical integration. No indication of "topping out" on M&A; will remain opportunistic and strategic.

Recent Developments

Q3 FY2026 earnings (announced 02-Apr-2026): EPS $1.60 vs. consensus, margin compression across shell eggs (conventional -72% pricing, -6.7% volume; specialty -12.1% pricing, +5.8% volume).
Board changes: Jim Poole (longtime member, 20+ years) passed away in Feb; Dudley Woolley appointed to fill vacancy (risk management, governance, operational growth expertise).
Prepared foods M&A: Echo Lake Foods acquisition integration ongoing; 17M lbs scrambled egg capacity & 12M lbs pancake-line capacity added through FY2027.
Joint venture: Fannie Foods partnership investing $7M through FY2028 for ~18M lbs expanded capacity.
Creighton Brothers/Crystal Lake acquisition (announced during Q3): Adds shell egg assets, liquid egg capacity, geographic scale.
Board expansion (Jun-2026): Added Michael Highfield and Haley Fisackerly as independent directors (board now 10 members).

Bull Narrative

Structural/Secular:

Eggs aligned with high-protein, health-conscious consumer trends; non-discretionary once consumer in channel.
Retail volumes +3% YTD despite commodity price swings; multi-segment growth (conventional, cage-free, free-range, pasture-raised).

Portfolio Evolution & Margin Quality:

Specialty eggs now >50% of mix; offer higher, more stable margins + structured pricing (40–88% of specialty under fixed/cost-plus).
Prepared foods emerging as durable, higher-margin growth platform (target 19–20% gross margin long-term).
Vertical integration (shell egg → liquid egg → prepared foods) improving supply security and unit economics.

Execution & Capital Discipline:

Management credibly executing on multi-year strategic plan despite cyclical headwinds.
Strong balance sheet ($1.15B cash, zero debt) allows opportunistic M&A + organic CapEx + shareholder returns.
Hybrid pricing model working as designed: downside protection in soft markets; management prioritizes earnings quality over upside capture.

Institutional Interest:

Recent board additions and insider buying (per Acquirer's Multiple, Feb 2026) signal confidence.
Valuation appears reasonable relative to deep-cycle trough (2.6 P/E at trough, note analyst commentary).

Bear Narrative

Cyclical & Commodity Risk:

Q3 earnings collapse (EPS -90%, operating income -94%) reminds investors this is a volatile, commodity-linked business.
High-path AI still present; depopulation recovery driving prices down despite demand stability.
Conventional egg pricing fell to $0.85 from $2.69 within single quarter—structural pricing power limited.
Feed costs subject to geopolitical shocks (grain, fertilizer, fuel); management acknowledges but can only "navigate" via inventory management.

Prepared Foods Execution Risk:

Q3 prepared foods margin trough; recovery trajectory speculative (guidance assumes full ramp by 2027–2028).
Recent acquisitions (Echo Lake, Crapini, Creighton/Crystal Lake) and integration execution unproven at scale.
Prepared foods now only 9.5% of sales; margin pressure from underabsorbed fixed costs during network optimization shows vulnerability.

Guidance & Transparency:

No formal EPS or revenue guidance; reliance on "normalized earnings power" is vague.
Management's framing of Q3 as "test of strategy" may obscure genuine demand/margin headwinds in prepared foods.
Lack of segment margin disclosure makes it hard to assess true profitability of specialty vs. prepared foods.

Competitive Pressure & Saturation:

Retail partners exploring contract-based pricing; promotional activity picking up in specialty segment suggests rising competition and potential margin compression ahead.
M&A and capacity expansion could signal market saturation; incremental returns on $7–35M annual prepared foods CapEx unclear.

Valuation & Dividend Risk:

Recent dividend of $0.36 per 100 shares questioned by retail investors ("why so low?"); variable dividend ties earnings to volatility.
If normalized earnings power compressed by competition or feed costs, dividend sustainability at risk.

Retail Sentiment

Tone: Mixed-to-Bullish with Caveats

Bullish Posts:

@QEInfinity (Jun 2026): "Solid balance sheet, good valuation, people aren't going to stop eating eggs."
@Bazzzigar (multiple, May–Jun 2026): Recurring "Bullish" tags; minimal commentary.
@Robertbirch (May–Jun 2026): Bought position citing protein boom and favorable valuation vs. 10-year mean.
@Estimize watchers: Expectations stable (~$0.53–$0.58 Q4 EPS) suggest modest expectations-reset rather than panic.

Bearish/Skeptical:

@angryron (May 2026): "If it's a great divi stock why did it pay only $35 per 100 shares?"—skepticism on dividend adequacy.
@Guntz (May 2026): "I miss when dividend stocks moved up when rest of market went down"—frustration with non-correlated behavior.
@Lreyn84702 (Jun 2026): "This stock appears to move on fuel prices... goes down either way"—perception of downside asymmetry.

Retail Conviction: Low-to-Moderate Forum chatter is sparse and fragmented; positions noted as small ("position just for fun"). No viral bull case or evidence of retail accumulation. Mostly passive observers awaiting Q4 / FY2027 guidance.

Caveats

No EPS Guidance: Management deliberately avoided formal forward guidance; "normalized earnings power" is subjective. Harder to stress-test scenarios.
Segment Margin Opacity: CALM does not break out margins by specialty vs. conventional vs. prepared foods. Difficult to independently verify management's profitability claims for each segment.
Prepared Foods Timing Risk: Recovery projections span 18–24 months and assume no integration stumbles, no demand softness, and cost-structure reductions materializing on schedule. Speculative.
AI Persistence: While "meaningfully lower," high-path AI supply disruption is not resolved. Any resurgence could upend specialty pricing stability narrative.
Feed Cost Assumptions: Management stated "90% of inputs already in the market," implying hedged for this planting season. Beyond FY2027, exposure unclear.
Acquisition Track Record: Echo Lake, Creighton, Crapini are recent; limited evidence of accretive contribution or margin realization vs. plan.
Analyst Coverage: Sparse detailed commentary in material. Most recent public analysis is pre-earnings positioning (Seeking Alpha, Acquirer's Multiple). Post-earnings buy-side research gaps.
Retail Investor Base: Forum engagement is light; retail conviction low. Index fund / insider holdings may dominate; retail sentiment not a strong signal.

Summary for Investment Council

Cal-Maine is executing a deliberate, multi-year pivot from volatile commodity shell eggs toward higher-margin, more-contracted specialty eggs and prepared foods. Q3 earnings collapse is real but framed by management as cyclical trough amid AI supply recovery, not demand failure. Specialty pricing remains anchored to fixed/cost-plus contracts; conventional hybrid pricing offers downside resilience at the cost of upside cap.

Key Strengths:

Fortress balance sheet; no debt; disciplined capital allocation.
Structural egg demand tailwinds (protein, convenience).
Mix-shift strategy credible in execution (specialty now >50%, prepared foods >9%).

Key Risks:

Commodity volatility remains severe (Q3 -90% EPS); normalized earnings power is speculative.
Prepared foods margin recovery dependent on flawless 18–24-month ramp; unproven at scale.
Guidance vacuum and segment margin opacity limit transparency.
Competitive intensity (promotional activity, contract proliferation) suggests margin pressure ahead.

Investor Profile Match:

Suitable for long-term, cyclically-insensitive portfolios; unsuitable for near-term alpha.
Dividend income attractive only if normalized earnings power holds; dividend risk if margins compress further.
Valuation reasonable at trough; upside capped by structural commodity dynamics and execution risk on prepared foods.

Bull case

Value and referee lenses (Greenblatt 82, Damodaran 82, Graham 78, Greenwald 78, Marks 72, Dalio 74) converge on a genuine mispricing: at ~2.5x EV/trailing FCF the market is pricing near-permanent earnings collapse for a debt-free, cash-rich (>$1.15B), largest-US-egg-producer with a 5.5x current ratio. Even conservative normalized FCF of $300-500M yields EPV/intrinsic values of roughly $94-160/share — comfortably above $80. The specialty egg mix (>50%, mostly fixed/cost-plus) and prepared foods pivot are real structural improvements that dampen commodity volatility over time. AI/disruption risk is near-zero for a physical biological commodity. Honest variable-dividend policy and disciplined capital allocation round out a low-risk, low-correlation (beta 0.22) holding.

Bear case

Quality lenses (Terry Smith 32, Munger 55, Akre 52, Buffett 58, Mauboussin 58) and Druckenmiller (28) see a commodity price-taker with no durable moat: conventional egg prices swung $2.69 to $0.85 in a single quarter, EPS collapsed 90% YoY, and FY2020-2023 history shows FCF ranging from -$69M to $304M. The headline P/E of 3.1x is a cyclical-peak trap — normalized P/E is likely 15-27x, making the stock fair-to-fully-valued, not deeply cheap. The stock is at a 52-week low with a rolling-over tape, no forward guidance, no near-term catalyst, and serial prepared-foods M&A (Echo Lake, Creighton, Crapini, Van's) with opaque segment margins and unproven integration.

Dissent — where the council disagrees

The sharpest split is quality vs. value/referee. Terry Smith (AVOID 32) and Druckenmiller (AVOID 28, high conviction) argue this is a moatless cyclical rolling over into a trough with a backward-looking cheap multiple and no inflection catalyst — the tape making new lows validates the deterioration. This matters because the entire long thesis rests on normalized FCF, which nobody can pin down: estimates range from $200M (bear) to $700M (Mauboussin base). Every lens, including the bulls, explicitly rejects the DCF's $756 intrinsic value as a peak-FCF artifact. The forensic short-seller (PASS 78) neutralizes the accounting/fraud angle — clean 1:1 cash conversion, zero debt — but flags that the margin of safety is 'illusory' if the cycle reverts. Net: the value case is real but rests on an unknowable normalization number, and the quality dissenters are right that this is not a compounder.

Key risks

Normalized earnings power is deeply uncertain — FCF has ranged from -$69M to $1.06B; at trough ($200-300M) fair value may be only $55-75, below current price
Commodity price-taker with no durable moat in conventional eggs; avian flu and feed costs are exogenous binary drivers
Prepared foods M&A (4 deals in ~18 months) unproven at scale with no segment margin disclosure — diworsification and integration risk
Cyclical peak-earnings trap: 3.1x P/E reflects last year's supercycle, not forward trajectory; tape at 52-week low
No forward guidance; 'normalized earnings power' framing is vague and unverifiable

Catalysts

Prepared foods hitting 19-20% target margins by Q4 FY2026 / FY2027 on schedule
Specialty egg margins proving sticky through a full commodity down-cycle
Avian flu resolution stabilizing conventional egg pricing and supply
Accelerated buybacks deploying the $1.15B cash hoard at trough valuations
Egg price mean-reversion off trough lifting reported earnings

DCF valuation (finance-expert model)

two-stage DCF, Gordon terminal value, CAPM-weighted WACC.

Intrinsic value: $756.50/share vs price $80.23 → +843% (bear $566.7 · base $756.5 · bull $756.5).

Step	Value
Base free cash flow	$1.1B
FCF growth (yrs 1-5)	12.0% (revenue CAGR)
WACC (β 0.222)	7.0%
Terminal growth	2.5%
PV of explicit FCF	$6.1B
PV of terminal (residual) value	$30.4B (83% of EV)
Enterprise value	$36.5B
less Net debt	$-140M
= Equity value	$36.7B
/ Shares (48M) = intrinsic/share	$756.50

⚠️ intrinsic value diverges >100% from price — treat as indicative; check FCF normalization (lumpy/one-off cash flows)

Short-sell evaluation

🚫 AVOID SHORTING

Despite decelerating fundamentals (EPS -90% YoY) and a broken tape, this is a poor short. The forensic short-seller (PASS 78) finds it fails nearly every red-flag test: clean 1:1 cash conversion, essentially zero debt ($641K), $1.15B cash, current ratio 5.5x, no restatements, no cluster selling. Even on aggressively normalized FCF the stock trades at only ~6-10x with net cash and asset backing (~1.86x book, ~$42/share equity), so the downside is limited and multiple referees see fair-to-cheap value. Shorting a debt-free, cash-generative, family-controlled market leader that is already 37% off its highs and pricing in trough earnings offers unattractive asymmetry — most of the bad news is already in the price.

Pros (the short could work)

Cyclical peak earnings mean-reverting hard — EPS -90% YoY, revenue -53%; trailing multiples are misleadingly low on peak FCF
Commodity price-taker with no durable moat; conventional egg pricing collapsed 68% in one quarter
Serial prepared-foods M&A with opaque segment margins — potential integration disappointment and hidden goodwill risk
No forward guidance; if normalized FCF settles near $200-300M, fair value could fall to $55-75, below current price
Feed cost exposure unhedged beyond FY2027; avian flu resurgence risk

Cons (what kills the short)

Fortress balance sheet: zero debt, $1.15B cash (~30% of market cap), 5.5x current ratio — no financing catalyst for a short
Trades at only ~6-10x normalized FCF with net cash and 1.86x book — limited downside, most bad news already priced
Clean forensic profile: 1:1 cash conversion, no restatements, no cluster insider selling, honest variable dividend
Already 37% off highs at 52-week low — poor entry, much of the cyclical decline has occurred
Family-controlled, low beta (0.22), active buybacks/dividends deploying cash — squeeze and mean-reversion risk against a short
Egg prices are volatile both ways; an avian flu resurgence would spike prices and torch a short instantly

Council scorecard

Lens	School	Stance	Score	Conf
Valuation Referee (Damodaran-style)	referee	🟢 pass	82	medium
Joel Greenblatt	value	🟢 pass	82	high
AI & Disruption Referee (Christensen-style)	referee	🟢 pass	82	high
Benjamin Graham	value	🟢 pass	78	medium
Bruce Greenwald	value	🟢 pass	78	medium
Forensic Short-Seller (Chanos/Einhorn-style)	referee	🟢 pass	78	medium
Ray Dalio	risk	🟢 pass	74	medium
Howard Marks	risk	🟢 pass	72	medium
Warren Buffett	quality	🟡 watch	58	medium
Seth Klarman	value	🟡 watch	58	medium
Peter Lynch	growth	🟡 watch	58	medium
Walter Schloss	value	🟡 watch	58	medium
Michael Mauboussin	quality	🟡 watch	58	medium
Charlie Munger	quality	🟡 watch	55	medium
Chuck Akre	quality	🟡 watch	52	medium
Terry Smith (Fundsmith)	quality	🔴 avoid	32	high
Stanley Druckenmiller	risk	🔴 avoid	28	high
Philip Fisher	growth	⚪ abstain	—	high

Member reasoning

Valuation Referee (Damodaran-style) — 🟢 pass · 82/100 · medium confidence

Cal-Maine is a textbook case where the market price appears to imply deeply pessimistic expectations — expectations that are implausible even under conservative assumptions. The DCF in the fact base produces an intrinsic value of ~$756/share vs. $80.23 market price, an ~840% implied upside. While this DCF warrants scrutiny (the 12% FCF growth assumption borrowed from a 3-year revenue CAGR during an egg-price supercycle is aggressive, and the 83% terminal value weight is dangerously high), even a brutal stress test arrives at a very wide margin of safety. Let me reverse-engineer what the current price requires: at $80.23 with ~48.5M shares, market cap is ~$3.8B. With $1.152B cash and essentially zero debt, enterprise value is roughly $2.65B. Against trailing FCF of $1.06B, the market is pricing CALM at roughly 2.5x EV/FCF — implying either (a) FCF collapses toward zero in perpetuity, or (b) the business is worth no more than 2-3 years of its current cash generation. For a company that is virtually debt-free, generates 36% operating margins (even if cyclically elevated), has a current ratio of 5.46, and is actively growing its specialty egg mix (>50% of shell egg sales) and prepared foods business, this is an extraordinarily low bar. The key analytical question is normalization: what is the 'true' mid-cycle FCF? Historical FCF ranged from -$69M (2020) to $304M (2023) to $1.06B (2024). A reasonable mid-cycle estimate — averaging good, mediocre, and bad years — might land around $350-500M. Even at $400M normalized FCF, applying a 7% WACC and 2.5% terminal growth gives a terminal value of ~$8.9B and a rough intrinsic value per share of $140-160, still a 75-100% premium to current price. The WACC used in the provided DCF (7%) is defensible given beta of 0.22 and virtually zero financial leverage — this is genuinely a low-risk business from a balance sheet standpoint even if earnings are volatile. The cost of equity at 5.41% may be slightly too low (implied by CAPM with a very low beta), and a more conservative 8-9% WACC would reduce intrinsic value materially — but even at 9% WACC with $400M normalized FCF, intrinsic value likely exceeds $100/share. The growth assumption is where the provided DCF overreaches: projecting 12% FCF growth on a base already inflated by a commodity supercycle is not credible as a 5-year base case. The market is right to be skeptical of peak earnings. However, the story-to-numbers conversion for CALM does not need heroic growth to justify the price: structural specialty egg mix shift (higher, more stable margins, 40-88% under fixed/cost-plus contracts), prepared foods (target 19-20% gross margins, currently ~9.5% of revenue and growing), fortress balance sheet enabling counter-cyclical M&A, and stable consumer demand for eggs as a non-discretionary protein all support a credible normalized earnings base. Reinvestment quality is strong: ROIC of 59% (even adjusting downward heavily for cyclicality, say to 15-20% normalized) comfortably exceeds any reasonable WACC estimate. Sales-to-capital ratio is high, meaning growth does not require voracious reinvestment — capital-light characteristics hold even in prepared foods expansion. The terminal value concentration (83% of DCF value) is a legitimate concern, but it exists partly because the explicit period cash flows are themselves large — the math amplifies it. Using a conservative terminal growth of 2% and normalizing FCF downward still produces significant intrinsic value. The provided DCF's bear case of $566/share is still 7x the current price, which strains credulity — suggesting the model's base FCF is the real issue, not the WACC or growth methodology. The market is essentially pricing in permanent secular decline toward near-zero earnings. This is the core mispricing hypothesis: the market is treating a cyclical trough as a structural impairment, confusing temporary commodity price mean-reversion with permanent earnings destruction. Risks are real: prepared foods execution is unproven, AI uncertainty persists, feed cost exposure exists beyond FY2027, and the variable dividend structure creates income uncertainty. But these risks are priced many times over at 2.5x EV/FCF.

Key points

Reverse-engineered implied expectations at $80.23 are catastrophic (~2.5x EV/trailing FCF) — the market prices permanent near-zero earnings, which is not supported by any plausible normalized scenario
Even at $400M normalized FCF (well below FY2024 actuals, approximately mid-cycle), intrinsic value likely ranges $120-180/share under conservative WACC assumptions — substantial margin of safety
ROIC of 59% (even heavily discounted to 15-20% for normalization) remains well above a defensible 7-9% WACC — growth is value-creating, not value-destructive
Capital efficiency is high: nearly zero long-term debt ($641K), current ratio 5.46, $1.15B cash — WACC of 7% is defensible and not the product of assumption-torture
Specialty egg mix shift (>50% of shell eggs under more stable pricing) and prepared foods growth (9.5% of revenue, targeting 19-20% margins) represent credible structural improvements to normalized earnings quality
Provided DCF base FCF assumption ($1.06B) is likely too high for a sustained 5-year projection — true mid-cycle FCF normalization is the key valuation variable; even $400M base produces significant upside
Terminal value concentration (83%) is elevated but partly a function of genuinely large near-term cash flows; manageable under sensitivity analysis with lower normalized FCF base

Red flags

Provided DCF projects 12% FCF growth from a cyclical peak FCF base — this is aggressive and inflates the intrinsic value to implausible levels (~$756/share); investors should use a normalized FCF base of $350-500M instead
Historical FCF volatility is extreme: -$69M (2020), $54M (2021), $726M (2022), $304M (2023), $1.06B (2024) — makes any single-year DCF base unreliable; normalization is essential and uncertain
83% terminal value weight in the fact-base DCF is a warning sign — though partially offset by reducing the base FCF, sensitivity to terminal growth rate and WACC is high
Prepared foods margin recovery (target 19-20%) is speculative over 18-24 months; no segment-level margin disclosure makes verification impossible — story-number disconnect risk exists here
No formal management guidance; 'normalized earnings power' framing is vague and investor-unfriendly from a DCF transparency standpoint
Feed cost exposure beyond FY2027 is unhedged and could compress margins in ways not captured in current profitability metrics
Variable dividend structure (tied to earnings) means the income component of total return is unreliable — not a DCF risk per se but affects income-seeking capital allocation

Joel Greenblatt — 🟢 pass · 82/100 · high confidence

Cal-Maine Foods is a textbook Magic Formula candidate: a high-ROIC business trading at an extraordinarily high earnings yield. On the ROIC axis, CALM earns exceptional returns on tangible capital — EBIT of ~$1.54B on a capital base that is nearly debt-free with working capital and fixed assets dwarfed by earnings power. Net working capital (current assets $1.42B minus current liabilities $0.26B = ~$1.16B) plus net fixed assets (total assets $2.49B minus current assets $1.42B minus intangibles, approximated as ~$1.07B) yields a tangible capital base roughly in the $1.5–2.0B range, against EBIT of $1.54B — implying ROIC on Greenblatt's denominator well north of 75-100%, a genuinely exceptional figure. On the earnings yield axis: EV = market cap $3.80B + long-term debt ~$0 (essentially nil at $641K) minus excess cash (~$140M cash + substantial short-term investments) = EV roughly $3.66B or less; EBIT $1.54B / EV ~$3.66B = earnings yield ~42%. That is an extraordinary figure by any Magic Formula screen. Even adjusting for current-year EBIT being a cyclical peak (Q3 FY2026 shows sharp earnings collapse to ~$1.60/share EPS vs ~$10.38 prior year), a trough-normalized EBIT of perhaps $300–500M still yields an earnings yield of 8–14% on current EV — acceptable on the quality/cheapness combination. The balance sheet is a fortress: virtually zero long-term debt ($641K), current ratio 5.46, ~$1.15B in cash and equivalents plus short-term securities. FCF conversion is excellent: $1.06B FCF on $1.54B operating income. The business generates real, repeatable operating earnings with minimal capital reinvestment (capex only $161M on $4.26B revenue). The primary Greenblatt concern is cyclicality: EBIT swings violently with egg commodity prices (Q3 FY2026 operating income collapsed ~94% YoY), meaning the Magic Formula inputs are highly sensitive to the measurement period. However, Greenblatt explicitly accounts for normalized earnings — and even at a severely punished trough, the combination of near-zero debt, massive cash buffer, and dominant market position keeps the formula attractive. The specialty egg mix shift (now 50%+ of volume) and hybrid pricing contracts are structurally reducing earnings volatility, which improves the reliability of normalized EBIT estimates. No special-situation catalyst is present (no spinoff, restructuring), but the formula stands strongly on its own two legs. The Van's Foods acquisition and board expansion are incremental positives but not transformative. Score 82: strong pass on both axes with a cyclicality discount applied.

Key points

EBIT/EV earnings yield ~42% on trailing EBIT; even at trough-normalized EBIT the earnings yield remains compelling (~8-14%)
ROIC on Greenblatt's tangible capital denominator (NWC + net fixed assets) likely exceeds 75-100% — top-decile quality
Virtually zero financial leverage ($641K long-term debt); ~$1.15B cash fortress eliminates EV distortion from hidden debt
FCF conversion excellent: $1.06B FCF / $1.54B EBIT with capex only $161M — real, repeatable owner earnings
Specialty egg mix at 50%+ with fixed/cost-plus contracts structurally reduces EBIT volatility, improving normalized input reliability
Scores on BOTH Magic Formula axes simultaneously — the combination Greenblatt prizes over either metric alone

Red flags

Severe cyclicality: Q3 FY2026 EBIT collapsed ~94% YoY — trailing EBIT is a peak figure, not a normalized figure; Magic Formula inputs require heavy normalization
Commodity-linked pricing means EBIT/EV can look artificially high at cycle peak; must stress-test at trough normalized EBIT to validate cheapness
No special-situation catalyst (no spinoff, restructuring) — purely a formula play without an additional mispricing mechanism
Prepared foods acquisitions (Echo Lake, Creighton Brothers) are early-stage integrations with unproven margin accretion; could dilute ROIC if capital deployed poorly
Variable dividend policy reduces income visibility; retail confusion about dividend adequacy suggests market may not properly understand the capital return mechanism
DCF intrinsic value (~$756/share) appears wildly overstated — uses peak FCF as base and 12% growth rate; treat as noise, not signal

AI & Disruption Referee (Christensen-style) — 🟢 pass · 82/100 · high confidence

Cal-Maine Foods is a physical agricultural producer — it grows, processes, and distributes eggs. The core 'job' the company does for customers is producing a physical protein commodity through vertically integrated farming, processing, and cold-chain distribution. AI cannot lay eggs, operate henhouses, or replace the physical supply chain. The obsolescence question resolves quickly: there is no plausible AI mechanism that substitutes for the biological and logistical reality of egg production. This is about as far from a knowledge-work or intermediary business as one can find in a public market. That said, AI is not irrelevant — it operates as a moderate tailwind on the cost side (precision feeding, flock health monitoring, automated grading/sorting, route optimization) and a mild threat on the demand side (lab-grown protein alternatives, plant-based substitutes) over a 10-year horizon. The disintermediation test fails almost completely: Cal-Maine does not sit between two parties as a matching or routing layer; it IS the physical production asset. The moat — scale, hatchery infrastructure, cold-chain distribution, USDA-certified facilities, specialty egg certifications, long-term retail contracts — is not replicable by a foundation model plus customer data. If anything, AI-enabled precision agriculture (optimizing feed conversion ratios, early disease detection, predictive depopulation scheduling) compounds the cost advantage of a scaled, data-rich operator versus smaller, less-instrumented competitors. The one genuine AI-adjacent risk is on the demand destruction side: if cultivated egg protein or AI-optimized plant-based substitutes reach cost parity with conventional eggs within the decade, volume growth assumptions weaken. However, this timeline is speculative; current cultivated egg economics are orders of magnitude above commodity egg prices (~$0.10-0.15/egg), and retail behavior shows no substitution signal (volumes +3% YTD per management). The prepared foods pivot (Echo Lake, liquid eggs) actually increases resilience — processed/ingredient formats are stickier and less subject to direct consumer substitution. Management's Q3 2026 earnings call discusses AI only in the context of avian influenza supply dynamics ('AI-driven supply recovery'), which is appropriate framing for their business — this is not denial of technology risk but accurate industry-specific use of the acronym. No commoditization signals visible: take rates stable, no AI-native competitors undercutting egg production, no self-service substitution pathway. The falsifiable bear case would be: (1) cultivated egg protein achieves <$0.20/egg production cost by 2030 and gains retail shelf placement, OR (2) AI-optimized vertical farming (controlled-environment poultry) achieves 30%+ cost advantage over conventional cage-free, attracting hyperscaler or CPG capital into the supply chain. Neither is imminent. The falsifiable bull case confirmation: Cal-Maine deploys precision-ag AI tools to widen feed-cost efficiency gap vs. smaller competitors, using flock-scale data advantages, while prepared foods margin recovery (targeting 19-20%) materializes on schedule — both would be visible in operating margin and market share data by FY2027-2028.

Key points

Core product is a physical biological commodity — no AI mechanism substitutes for egg production; obsolescence risk is near-zero on 3-10 year horizon
Disintermediation test fails completely: CALM is the physical asset, not a matching/routing intermediary between two parties
AI tailwinds on cost side (precision feeding, flock health monitoring, automated grading) modestly compound scale advantages for large operators like CALM vs. smaller competitors
Prepared foods expansion (liquid eggs, scrambled eggs, pancake mixes) increases product mix resilience against any future direct substitution in shell egg segment
Specialty egg mix now >50% of sales with 40-88% under fixed/cost-plus contracts — pricing stability not dependent on any algorithmic or digital intermediary function
Virtually zero long-term debt and $1.15B cash provide capital to adopt AI-enabled precision agriculture tools as they mature — acquirer rather than victim
Management's use of 'AI' in earnings context refers to avian influenza — accurately framed for their industry, not a technology denial signal

Red flags

Long-horizon demand risk from cultivated egg protein if production economics improve dramatically (currently orders of magnitude above commodity egg prices — not imminent but warrants monitoring by 2028-2030)
AI-optimized controlled-environment agriculture (vertical/indoor poultry) could theoretically attract hyperscaler or CPG capital given data/optimization framing — very early stage but a legitimate 10-year watch item
Feed cost exposure (grain, fertilizer) could be partially addressed by AI-driven commodity hedging platforms that larger competitors or trading firms deploy more aggressively — execution risk, not an existential threat
Prepared foods segment margins are currently opaque (no segment disclosure); AI-enabled competitors in prepared/packaged foods (e.g., AI-optimized product formulation, distribution) could pressure margins in this nascent segment before CALM achieves scale

Benjamin Graham — 🟢 pass · 78/100 · medium confidence

Cal-Maine Foods presents a genuinely unusual value proposition by Graham's standards: a commodity business trading at a P/E of 3.12x, P/B of 1.86x, and P/S of 0.89x with a current ratio of 5.46, essentially zero long-term debt ($641K), and demonstrated positive earnings across the observable multi-year history. The Graham combined metric (P/E x P/B = 3.12 x 1.86 = 5.8) is dramatically below his 22.5 ceiling. Earnings yield of 41.97% dwarfs any high-grade bond yield. The balance sheet is a fortress: $1.424B current assets vs. $261M current liabilities; net current assets (NCAV) of approximately $1.164B vs. total liabilities of $439M means current assets alone cover ALL liabilities 3.2x over — a classic Graham defensive screen met emphatically. Working capital (~$1.163B) vastly exceeds long-term debt (~$641K). The primary Graham concern is earnings stability and cyclicality: the history shows a near-zero net income year in 2020, a volatile swing from $2M to $1.22B net income across five years, and a Q3 FY2026 EPS collapse of ~90% YoY. This is not the stable, predictable earnings stream Graham preferred — it is a commodity business whose profitability is hostage to egg pricing and avian flu outbreaks. However, at current valuations, the price appears to already fully discount a severe normalized earnings environment. Even at trough-cycle earnings (e.g., 2020's near-zero), the balance sheet alone provides substantial downside cushion. The DCF intrinsic value of $756/share vs. $80.23 is extreme and should be treated skeptically given FCF cyclicality; however, even a deeply conservative normalization (say, 50% haircut to peak FCF, 10x multiple) yields values well above current price. The dividend is variable and therefore unreliable by Graham's preferred standard, which is a genuine demerit. Net-net test is not met (market cap $3.8B vs. NCAV ~$1.16B), but the NCAV figure still provides meaningful asset backing. The Van's Foods acquisition and board expansion are minor governance positives. Overall: exceptional quantitative value scores on every balance-sheet and earnings-multiple metric; primary risk is earnings volatility inherent to commodity agriculture, which Graham would discount but not disqualify given the asset protection offered.

Key points

P/E of 3.12x and earnings yield of 42% vastly exceed Graham's defensive bar and dwarf high-grade bond yields
Graham combined metric P/E x P/B = 5.8, well below the 22.5 ceiling
Current ratio of 5.46 and current assets ($1.424B) cover ALL liabilities ($439M) by 3.2x — exceptional balance-sheet strength
Long-term debt of $641K vs. working capital of ~$1.163B: debt is effectively zero, a Graham ideal
NCAV (~$1.16B) exceeds total liabilities; while not a classic net-net vs. market cap, asset backing is substantial
P/B of 1.86x is moderate; the asset base is real (hard assets: hens, farms, plants) not intangible-heavy
Revenue CAGR of 33.9% over three years is not a Graham criterion but confirms scale and market position
Fortress cash position ($1.15B per narrative) with no debt provides Mr. Market discipline opportunity — price is near 52-week low

Red flags

Severe earnings cyclicality: net income ranged from $2M (2020) to $1.22B (2024) — far from the stable earnings trajectory Graham preferred over a decade
Variable dividend tied to earnings is structurally unreliable; retail investor complaints about low payouts confirm this
Q3 FY2026 EPS -90% YoY illustrates how rapidly commodity pricing can devastate reported profitability
DCF intrinsic value of $756/share uses peak FCF as base and 12% growth — wildly optimistic for a commodity business; true normalized value is much lower, though still likely well above $80
Only 5 years of clear financial history in fact base; full 10-year earnings stability record not verifiable from provided data
Prepared foods acquisitions (Echo Lake, Creighton, Crapini) introduce integration risk and capital deployment into unproven higher-margin businesses — Graham would demand demonstrated results, not projections

Bruce Greenwald — 🟢 pass · 78/100 · medium confidence

Cal-Maine is a classic EPV candidate: a real operating business with a long earnings history, tangible asset base, and a cyclical commodity structure that demands normalization rather than peak-earnings capitalization. My framework proceeds in three steps: (1) normalize earnings power across the cycle, (2) estimate asset reproduction value, (3) read the EPV-vs-assets gap as a moat signal, and only then compare to market price.

Step 1: Normalized Earnings Power Value (EPV) The current year (FY2025, ended May 2025) is clearly a peak: revenue $4.26B, net income $1.22B, FCF $1.06B. Q3 FY2026 EPS collapsed 90% YoY to $1.60 — this is the trough. A proper cycle normalization must span both. Looking at history: FY2020 net income $2M, FY2021 $133M, FY2022 $758M, FY2023 $278M, FY2024 $1.22B. Revenue CAGR of ~33% over 3 years is noise driven by avian flu-induced egg-price spikes, not structural earnings growth. A rough mid-cycle operating margin is in the 10-15% range (FY2021 was ~7.5% net margin; FY2023 ~12%; FY2022/2024 are outlier peaks). Using mid-cycle net margin of ~12% on a normalized revenue base of roughly $2.5-3.0B (stripping AI-driven price spikes and assuming a return to more normal egg pricing), I estimate normalized net income of approximately $300-360M. Adjusting for the minimal capex-vs-D&A spread (capex $161M, D&A not separately disclosed but implied modest from asset base), NOPAT approximates $320M. Capitalizing at WACC of 7% (as provided, which is reasonable for this low-beta 0.22 stock): EPV = $320M / 0.07 = ~$4.57B equity value, or roughly $94/share (48.5M shares). This is above the current $80.23 price — EPV suggests modest undervaluation even on conservative normalized assumptions. The DCF intrinsic value of $756/share is wildly inflated by the 12% perpetual FCF growth assumption applied to peak FCF — I explicitly discard this as unhelpful and precisely the kind of terminal-value speculation my framework warns against.

Step 2: Asset Reproduction Value Total assets: $2.49B. Total liabilities: $439M. Book equity: $2.05B (~$42/share). However, reproduction value must include the real cost of rebuilding CALM's position: ~50M+ laying hens, processing facilities across the Southeast/Midwest, 50+ years of customer relationships with major retailers (Walmart, Kroger, etc.), brand equity in specialty segments, and the regulatory/permitting cost of building egg-production facilities (increasingly difficult given animal welfare regulations). I estimate reproduction value at 1.3-1.5x book = $2.67-$3.07B, or $55-63/share. This is a hard floor.

Step 3: Moat Signal — EPV vs. Reproduction Value EPV (~$94/share) substantially exceeds reproduction value ($55-63/share). This EPV > assets gap is the key signal: it implies CALM has real competitive advantages beyond what it cost to build the assets. The barriers are concrete: (a) scale economies — largest US shell-egg producer by volume, with distribution infrastructure that smaller producers cannot match cost-effectively; (b) customer captivity — long-term supply agreements with major retailers create switching-cost-like stickiness; (c) regulatory/permitting moat — cage-free and animal-welfare mandates create barriers that protect incumbents from new entrants; (d) geographic density — regional concentration allows logistics cost advantages. These are not vague 'brand' claims; they are structural. ROIC of 59% (peak) will clearly mean-revert, but even at mid-cycle ROIC of 15-20%, this exceeds cost of capital — suggesting franchise economics persist.

Step 4: Price vs. EPV At $80.23, price is BELOW my conservative EPV estimate of ~$94/share. This provides a genuine margin of safety relative to normalized — not peak — earnings power. Price/book of 1.86x is reasonable for a business with genuine franchise characteristics. The 36% discount to 52-week high ($126) reflects the Q3 earnings collapse, which is cyclical, not structural.

Key Risks to EPV: (1) Prepared foods acquisition bets — Echo Lake, Creighton Brothers integration could consume capital without clear ROIC visibility; (2) AI recurrence could reset the normalization baseline; (3) feed cost exposure beyond FY2027 when current hedges expire; (4) conventional egg pricing commoditization limits upside on the largest volume segment.

Key points

Normalized EPV of ~$94/share (using mid-cycle ~12% net margin on ~$2.75B normalized revenue, capitalized at 7% WACC) exceeds current price of $80.23 — genuine margin of safety exists without requiring any growth assumption
EPV substantially exceeds reproduction asset value (~$55-63/share), confirming a real franchise exists; barriers include scale economies, retailer stickiness, and regulatory/permitting moats that protect incumbents
Virtually zero long-term debt ($641K), $1.15B cash fortress, and current ratio of 5.46x mean balance sheet risk is negligible — this is a durable going concern
Peak FY2025 earnings (ROIC 59%, FCF $1.06B) will mean-revert but mid-cycle returns still clearly exceed cost of capital — franchise economics confirmed
Specialty eggs >50% of mix under fixed/cost-plus contracts provides partial anchor to earnings; reducing commodity swing sensitivity structurally over time
The provided DCF ($756/share intrinsic) is correctly flagged as indicative but deeply suspect — it applies 12% perpetual FCF growth to peak FCF, compounding terminal value to 83% of enterprise value; I treat this as noise, not signal

Red flags

Peak earnings normalization is critical and uncertain — FY2022 and FY2024/2025 are outlier years driven by avian flu price spikes; true mid-cycle earnings power requires further data to pin down precisely
Prepared foods acquisitions (Echo Lake, Creighton Brothers, Crapini) involve capital deployment with no visible segment margins or ROIC data — classic growth capex without confirmed moat-protected returns
Q3 FY2026 EPS collapse to $1.60 (-90% YoY) illustrates how violently conventional egg pricing moves — even a hybrid pricing model provides limited protection in a full commodity downturn
Variable dividend structure (tied to earnings) means income investors bear full commodity cycle risk — dividend sustainability at trough is constrained
No segment margin disclosure prevents rigorous verification of specialty vs. prepared foods profitability — opacity is a mild governance concern
52-week range ($71.92-$126.40) with current price at low end suggests market already pricing cyclical trough; margin of safety is real but not extreme

Forensic Short-Seller (Chanos/Einhorn-style) — 🟢 pass · 78/100 · medium confidence

Cal-Maine Foods is an unusual short-seller target precisely because it fails nearly every classic forensic red flag test. The earnings-vs-cash test is clean: net income of $1.22B vs. operating cash flow of $1.22B and FCF of $1.06B — cash conversion is nearly 1:1, which is the opposite of the accrual-fraud signal. The balance sheet is fortress-grade: long-term debt of $641K (not a typo — essentially zero), current ratio of 5.46, and $1.15B in cash. There is no debt wall, no refinancing dependence, no covenant risk. This is a business that could shut its doors tomorrow and return most of its market cap in cash. Governance signals are mixed-to-benign: recent board additions (two new independent directors) and a Form 3 filing for new directors are normal governance, not red flags. The insider activity in the filings is restricted stock grants to directors — not cluster selling. No auditor changes, no restatements, no going-concern language detected. Working capital is clean: current ratio 5.46, no evidence of receivables or inventory inflating faster than revenue in the data available (though DSO trend is not granularly disclosed). The one area where forensic scrutiny is warranted is the commodity earnings cycle: Q3 FY2026 EPS collapsed 90% YoY while the prior year's $1.22B net income was generated during an avian flu-driven egg price spike. The DCF using peak FCF as a base ($1.06B) and projecting 12% growth is wildly optimistic — the system's intrinsic value of $756/share vs. $80 current price is a DCF artifact of using cycle-peak cash flows, not evidence of value. The real forensic risk is 'earnings normalization disguised as growth story': if normalized FCF reverts toward $200-400M (the 2021-2023 average), the company is not cheap at $80. The prepared foods pivot (Echo Lake, Crapini, Creighton acquisitions) introduces serial-acquirer risk: integration costs buried in capex, goodwill not yet disclosed at scale, and prepared foods margins unverified. Segment margin opacity is a genuine information gap. However, none of this rises to a short thesis — the stock trades at 3.6x peak FCF and 1.86x book with zero debt. A short would require a catalyst that does not exist here in financial terms.

Key points

Earnings-to-cash conversion is nearly 1:1 ($1.22B net income vs. $1.22B OCF vs. $1.06B FCF) — the primary forensic test is clean
Long-term debt is $641K; current ratio 5.46; $1.15B cash — no debt wall, no financing dependence, zero covenant risk
No clustered insider selling detected; recent Form 4 activity is restricted stock grants to new directors, not executive liquidation
No auditor changes, restatements, or going-concern language in filings reviewed
DCF intrinsic value of $756/share is a cycle-peak artifact — base FCF of $1.06B is peak-cycle; normalized FCF 2021-2023 averaged ~$360M, implying far lower intrinsic value
Serial acquirer risk emerging (Echo Lake, Crapini, Creighton/Crystal Lake) with limited segment margin disclosure — integration execution unverified
Variable dividend model tied to earnings means dividend collapse in down-cycle is by design, not fraud
Q3 FY2026 EPS -90% YoY demonstrates extreme commodity earnings volatility; 'normalized earnings power' framing by management is vague and unverifiable without segment disclosure

Red flags

DCF using peak FCF wildly overstates intrinsic value; normalized FCF likely 60-70% lower, making the margin of safety illusory at current prices if cycle reverts
Prepared foods segment margin opacity: no disclosed gross margin by segment; management's 19-20% target is unverifiable from public filings
Serial acquisition pace (4 deals in ~18 months) with no granular goodwill or integration cost disclosure creates hidden liability risk
Variable dividend paid $0.36/share in Q3 trough vs. peak-cycle payouts — retail investors may not understand dividend model, creating sentiment dislocation risk
Q3 conventional egg price collapsed from $2.69 to $0.85 in a single quarter — pricing power is structural illusion when avian flu tailwind reverses
No explicit forward guidance issued; 'normalized earnings power' is management-defined, not auditable
Feed cost hedging disclosed as '90% of inputs already in market' only through near-term planting season — beyond FY2027, commodity exposure unhedged

Ray Dalio — 🟢 pass · 74/100 · medium confidence

Cal-Maine Foods is a commodity agricultural business whose macro profile is genuinely interesting from a Dalio regime-robustness lens. The business sells non-discretionary food (eggs) with inelastic demand — a critical test for regime durability. Let me stress-test across the four boxes: (1) Rising Growth + Rising Inflation (boom/reflation): CALM benefits as egg prices typically rise with general food inflation, feed costs are manageable if passed through, and consumer spending supports volume. Favorable. (2) Rising Inflation + Falling Growth (stagflation): This is the critical test. Eggs are a staple protein — consumers trade DOWN to eggs from meat, providing volume support. CALM has demonstrated ability to raise prices in inflationary environments (FY2022 and FY2024 both showed extraordinary revenue/earnings surges during inflationary periods). Feed costs (corn, soybean meal) are the primary input risk, but ~90% of inputs reportedly hedged near-term. Moderately favorable — better than most equities in stagflation. (3) Falling Growth + Falling Inflation (deflationary bust/deleveraging): This is the weakest box. Commodity egg prices collapse (as seen in Q3 FY2026 where conventional prices dropped from $2.69 to $0.85 per dozen). Revenue and earnings can swing -53% and -90% respectively in a single quarter. However, the fortress balance sheet (virtually zero long-term debt at $641K, $1.15B+ cash, current ratio 5.46x) means the company survives without distress. The variable dividend also self-adjusts, preventing dividend trap. Survivable but painful. (4) Rising Growth + Falling Inflation (goldilocks): Mixed — egg price normalization compresses margins from peak, but volume growth and specialty mix improvement compensate. The specialty pivot (now >50% of mix under fixed/cost-plus contracts) genuinely improves regime resilience by reducing pure spot exposure. On the debt cycle: CALM is the opposite of a credit-cycle risk — it carries essentially NO long-term debt ($641K), is a net creditor (cash-rich), and its customer base (retail grocery, food service) is not particularly credit-sensitive for egg purchasing decisions. This is not a business whose demand is pulled forward by cheap credit. Rate environment sensitivity: Near zero. No refinancing risk whatsoever. The company benefits from higher rates on its $1.15B cash hoard. This is a genuine positive in a higher-for-longer regime. Inflation pass-through: Historically strong during inflationary spikes (FY2022, FY2024 revenue/earnings surged). The specialty shift toward fixed/cost-plus contracts adds stability. Real asset exposure via physical layer flocks and production infrastructure provides implicit real-asset backing. Correlation/diversification value: Beta of 0.22 — one of the lowest in the market. Drivers are avian flu cycles, feed commodity prices, and consumer protein preferences — genuinely uncorrelated to financial cycle, rate cycle, and typical equity book. This is Dalio's 'Holy Grail' contribution: a return stream driven by biological/agricultural cycles rather than financial cycles. Key weaknesses from my lens: The commodity cyclicality is severe and the Q3 collapse illustrates single-quarter earnings can be near-zero. Geographic concentration is entirely domestic (US eggs) — no FX diversification. The DCF intrinsic value of $756/share vs. $80 price is almost certainly a DCF artifact (using peak FCF as base with 12% growth assumption on top of a commodity super-cycle — the valuation block's own caveat flags this). True normalized FCF is likely far lower than $1.06B. The prepared foods pivot introduces M&A integration risk. But on pure Dalio macro dimensions — regime robustness, debt cycle position, rate sensitivity, balance sheet resilience, inflation pass-through, low correlation — CALM scores well above average for an equity holding. It is not multi-geography, but it compensates with extraordinary balance sheet strength and genuine macro uncorrelation.

Key points

Near-zero long-term debt ($641K) and $1.15B+ cash: virtually no refinancing risk or rate sensitivity — benefits from higher-for-longer rates on cash reserves
Beta of 0.22 confirms genuinely uncorrelated return stream; agricultural/avian-cycle drivers are independent of financial cycle and typical equity book factors
Eggs are non-discretionary staple protein — demand is inelastic and consumers trade INTO eggs during stagflation (protein affordability thesis)
Specialty egg mix now >50% under fixed/cost-plus contracts reduces pure spot commodity exposure and improves regime robustness
Inflation pass-through historically strong: FY2022 and FY2024 earnings surged during inflationary environments; real-asset backing via physical layer flocks
Current ratio 5.46x, virtually zero debt, strong interest coverage — can absorb severe peak-to-trough earnings drawdown (Q3 -90% EPS) without distress or capital market access
Variable dividend structure self-adjusts in downturns, avoiding the dividend trap that destroys balance sheets in commodity busts
Demand not credit-cycle dependent: egg purchasing decisions by retail consumers and food service are not leveraged, so deleveraging scenarios don't compress demand the way they would for housing or autos

Red flags

Severe commodity cyclicality: Q3 FY2026 showed EPS -90% YoY and revenue -53% — single-regime (inflationary) earnings peak creates dangerous anchoring in DCF valuations
100% domestic (US) revenue concentration: no geographic or FX diversification, concentrated exposure to single regulatory and economic environment — violates Dalio's shifting world order framework
DCF intrinsic value of $756/share uses peak FCF ($1.06B) as perpetual base with 12% growth — almost certainly inflated; normalized through-cycle FCF is materially lower (FY2020: -$69M FCF, FY2023: $304M FCF)
Feed cost exposure (corn, soybean meal) creates stagflation vulnerability if grain prices spike faster than egg price pass-through — management claims 90% hedged near-term but beyond FY2027 exposure is open
Prepared foods M&A integration (Echo Lake, Creighton, Crapini) introduces execution risk and may erode capital allocation quality if returns disappoint — management track record on acquisitions is unproven at scale
No formal earnings guidance and segment margin opacity make independent stress-testing of 'normalized earnings power' difficult — reduces confidence in scenario analysis

Howard Marks — 🟢 pass · 72/100 · medium confidence

From a Marks risk lens, the central question is not 'is Cal-Maine a good business?' but 'what is priced in and is the cushion against permanent loss adequate?' At $80.23, CALM trades at a P/E of ~3x, price-to-FCF of ~3.6x, and price-to-sales of 0.89x against trailing-twelve-months earnings that are themselves elevated (AVIAN flu windfall years). The price is at its 52-week low — the stock has been cut from $126 to $80, a 36% decline, while the business remains operationally intact with $1.15B in cash and zero meaningful debt ($641K long-term debt). This is the classic Marks setup: a feared, out-of-favor name where the crowd is extrapolating a cyclical trough (Q3 EPS down 90% YoY) as if it represents permanent earnings power. The DCF intrinsic value of ~$757/share is almost certainly inflated by over-optimistic growth assumptions — using peak FCF of $1.06B as a perpetual base with 12% growth is heroically aggressive — but even haircut severely, the stock prices in near-zero normalized earnings power at current levels. My conservative framework: if normalized mid-cycle FCF is, say, $300-400M (roughly 2021-2023 average), the stock at $80 trades at ~6-10x normalized FCF with a fortress balance sheet. The balance sheet is the core of the margin of safety: current ratio of 5.46, stockholders' equity of $2.05B vs. market cap of $3.8B, cash of $1.15B, and virtually no debt. This structure can survive extended commodity troughs, avian flu disruptions, and feed cost shocks without existential risk — the key Marks criterion of 'ability to survive a bad scenario.' Second-level thinking: the consensus is clearly pricing near-term cyclical pain as permanent impairment. The Q3 EPS collapse is real, but the causes (avian flu supply recovery, egg price normalization) are well-understood and partially transient. Specialty egg mix has structurally improved (now 50%+ of sales under more stable pricing), which is a genuine business quality improvement not visible in the headline EPS decline. The main risks under my framework are: (1) the commodity trough is deeper and longer than 2022-2023 precedent, compressing normalized FCF below my estimate; (2) prepared foods expansion destroys capital at scale before returns materialize; (3) the DCF's 12% FCF growth assumption embedded in the model is wildly unrealistic and investors anchoring to it face disappointment. I do NOT give a high score because the business is inherently cyclical with limited pricing power in conventional eggs, the recent blockbuster earnings were avian-flu-driven one-offs that inflate trailing metrics, and prepared foods integration risk is real and unproven. But on a Marks risk/reward basis — distressed price, fortress balance sheet, low embedded expectations, no leverage risk — this clears my bar for a 'pass' at modest conviction.

Key points

Stock at 52-week low ($80 vs. $126 high) with 36% price decline; crowd extrapolating trough as permanent — classic contrarian setup
Fortress balance sheet: $1.15B cash, effectively zero debt ($641K LT debt), current ratio 5.46, stockholders equity $2.05B — structural survival ability in worst-case scenarios is extremely high
P/E 3.1x, price-to-FCF 3.6x, P/S 0.89x vs. trailing peak earnings; even applying severe normalization haircut (e.g., $300M normalized FCF), stock trades at ~10x — not demanding for a durable essential-food business
Specialty egg mix now >50% of sales under structured pricing (88% fixed/cost-plus contracts) — meaningful structural improvement in earnings quality vs. prior cycles, not priced in at current levels
Second-level view: Q3 EPS -90% is a cyclical trough driven by avian flu supply recovery + egg price normalization, not demand destruction or competitive displacement; the business retains its market-leading position
Capital allocation discipline demonstrated: ~$1B deployed in 12 months across dividends, buybacks, and strategic acquisitions while maintaining strong liquidity — management not destroying the balance sheet fortress
DCF at $756/share is almost certainly too high (uses peak FCF + 12% perpetual growth), but even at a 70-80% haircut to intrinsic value, price-to-value discount remains substantial

Red flags

Trailing fundamentals (net income $1.22B, FCF $1.06B) are heavily influenced by avian flu-driven egg price spikes — normalized earnings power is materially lower and difficult to estimate precisely; P/E of 3x is misleading at cycle peak
Prepared foods integration risk is real: Echo Lake, Crapini, Creighton acquisitions are recent and unproven at scale; 19-20% margin target over 18-24 months is management guidance without segment-level disclosure to verify
No formal earnings guidance from management; reliance on 'normalized earnings power' language creates transparency deficit that limits ability to judge what is truly priced in
Commodity cyclicality is structural and severe — conventional egg prices swung from $2.69 to $0.85 in a single quarter (Q3 2026); feed cost exposure beyond FY2027 is unhedged and subject to geopolitical shocks
DCF terminal value represents 83% of equity value with 12% near-term FCF growth from a peak base — model is dangerously optimistic if used uncritically; caveat in fact base correctly flags this
Dividend is variable and tied to earnings; $0.36/share recent payment signals earnings trough, raising questions about income investor support at current price levels
Avian flu risk is not fully resolved; any resurgence could paradoxically boost egg prices but further disrupt operations and supply-chain planning

Warren Buffett — 🟡 watch · 58/100 · medium confidence

Cal-Maine Foods presents a genuinely interesting but ultimately mixed case through my quality lens. On the positive side, it is the largest domestic shell egg producer with a ~20% market share, a near-fortress balance sheet (virtually zero long-term debt, $1.15B cash, current ratio of 5.5), and has historically generated impressive ROIC (59% reported, though this is trough-to-peak inflated by avian flu pricing). The business is understandable — they raise hens, sell eggs — and egg demand is as close to staple as it gets. Management appears honest and rational: variable dividend tied to earnings rather than promising what they cannot deliver, disciplined M&A with clear strategic rationale, and candid communication about cyclical headwinds.

However, the core concern from my perspective is whether this constitutes a durable economic moat or merely the temporary earnings power of a low-cost commodity producer during a supply shock. The evidence for durable pricing power is weak: conventional egg pricing fell from $2.69 to $0.85 in a single quarter (Q3 FY2026), EPS collapsed 90% year-over-year, and the company's profitability is heavily dependent on factors outside management's control — avian flu, feed costs, competitor flock recovery. This is the hallmark of a commodity business, not a moated franchise like See's Candies or Coca-Cola. The specialty egg pivot (now 50.5% of shell egg mix) and prepared foods expansion (9.5% of sales, targeting 19-20% margins) are strategically sound but unproven at scale and represent a directional bet rather than demonstrated franchise economics.

On valuation: the DCF intrinsic value of ~$756/share vs. current price of $80 looks absurd on its face, and the model's own caveats flag the issue — it is mechanically projecting FY2025 peak FCF ($1.06B, a likely once-in-decade AVIAN flu windfall) forward at 12% growth for five years, then applying a generous terminal multiple. This is egregiously optimistic. Normalized FCF for this business, absent supply shocks, is far lower — FY2021 produced $54M FCF and FY2023 produced $304M. A more honest normalized FCF might be $300-500M, yielding a very different intrinsic value. At $80/share and a $3.8B market cap, the price-to-normalized-FCF is roughly 8-13x — not egregiously expensive, but not a screaming bargain for a commodity business with volatile earnings. The P/B of 1.86x is fair for the asset base.

Management capital allocation in FY2025 was rational: $384M dividends, $299M acquisitions, $150M buybacks, $117M capex. The acquisitions (Echo Lake, Creighton Brothers) vertically integrate toward liquid eggs and prepared foods, which is sensible. But acquisition track record is short and unproven — this is empire-building risk I take seriously.

The bottom line: CALM is a well-run, financially strong company in an inherently commodity business. The specialty/prepared foods pivot could over time create franchise-like characteristics, but that case is not proven. I would need to see sustained specialty margins through a full cycle, prepared foods profitability at scale, and evidence that the mix shift durably improves normalized earnings power before paying up. At current prices, this is a watch — not a clear buy for a quality investor, not an avoid given the balance sheet and honest management.

Key points

Largest US shell egg producer (~20% market share) — low-cost scale advantage is real but commodity pricing power is not durable
Balance sheet is exceptional: essentially zero debt, $1.15B cash, current ratio 5.5 — can self-fund through any downturn
ROE of 60% and ROIC of 59% are inflated by peak avian-flu earnings; normalized ROE closer to 15-25% based on FY2021-2023 history
Specialty egg mix now >50% of shell egg sales with 40-88% under fixed/cost-plus contracts — meaningful structural improvement in earnings quality
Variable dividend policy is honest and shareholder-aligned; management communication is straightforward about cyclical volatility
At $80/share (~$3.8B market cap), P/normalized FCF of roughly 8-13x is reasonable but not cheap enough to be a compelling margin of safety for a commodity business
DCF intrinsic value of $756/share is mechanically unreliable — projects peak-cycle FCF forward; normalized value likely $150-300/share

Red flags

Conventional egg pricing collapsed 68% in a single quarter — quintessential commodity pricing with no durable moat
EPS fell 90% YoY in Q3 FY2026 — earnings volatility far too high for a quality compounder
Prepared foods (9.5% of sales) shows margin trough and execution risk; multiple recent acquisitions unproven at scale
DCF grossly overstates intrinsic value by anchoring to peak-cycle FCF; investors relying on it will overpay
Revenue history shows extreme cyclicality: $1.35B (FY2020) → $4.26B (FY2025) driven by exogenous avian flu, not franchise economics
No formal guidance and segment margin opacity makes independent verification of management's 'normalized earnings power' narrative difficult
Feed cost exposure and avian influenza recurrence remain binary risks that management cannot control or hedge fully

Seth Klarman — 🟡 watch · 58/100 · medium confidence

Cal-Maine presents a genuinely interesting value setup — fortress balance sheet, near-zero debt, substantial cash, and recently extraordinary earnings power — but the margin of safety calculation is murkier than it first appears. The headline numbers (P/E 3.1x, P/FCF 3.6x, P/S 0.89x) are based on FY2025 peak earnings of $1.22B net income during an avian flu-driven commodity supercycle. The Q3 FY2026 earnings collapse (-90% YoY EPS) is the market's preview of mean reversion. The DCF intrinsic value of $756/share vs. $80 current price looks fantastical and should be dismissed — it projects 12% FCF growth perpetually from a cyclical peak FCF of $1.06B, which grossly overstates normalized earnings power. A conservative Klarman-style appraisal must normalize earnings over the full egg price cycle. In 2023 (non-avian-flu trough), net income was $278M and FCF was $304M — implying a normalized P/FCF closer to 12-13x at current price, which is less dramatic but still not egregious for a dominant market leader. The balance sheet is the crown jewel: $1.15B cash, essentially zero long-term debt ($641K), current ratio 5.5x, stockholders equity $2.05B, and market cap of $3.8B. Book value per share is approximately $42 ($2.05B / 48.5M shares), so price-to-book is 1.86x — not a net-net, but tangible asset backing is real. The company is trading at roughly 1.85x tangible book with a cash hoard equal to ~30% of market cap. Liquidation value is meaningful. The prepared foods pivot and specialty egg mix shift are credible strategic moves but introduce execution risk and extend the timeline to realize earnings normalization. The DCF's reliance on 12% growth from peak FCF is precisely the optimistic-forecast trap Klarman warns against. Stripping that out, normalized FCF of perhaps $300-500M (blending 2023 trough and more moderate avian-flu recovery) at a 7% WACC yields intrinsic value of roughly $85-130/share — meaning the current price of $80 offers a thin to moderate margin of safety, not the enormous cushion the headline multiples suggest. The stock is at its 52-week low ($71.92 low, current $80.23), is 36% off its 52-week high of $126, and institutional accumulation is noted. These are Mr. Market features worth respecting but not sufficient alone. The primary concern from a downside-first perspective: if egg prices normalize to pre-avian-flu levels and prepared foods margins disappoint during the 18-24 month ramp, normalized FCF could fall to $200-250M, implying a fair value of $55-75/share — offering limited downside protection from current prices. The margin of safety exists but is not wide enough to be a high-conviction Baupost position; it's a 'watch' — revisit if price falls to low-to-mid $60s or if a specific catalyst (e.g., significant buyback acceleration, strategic transaction, or clear AI impact recovery timeline) narrows the uncertainty band.

Key points

Balance sheet is exceptional: $1.15B cash, $641K long-term debt, current ratio 5.5x — genuine downside floor from asset backing
Normalized earnings power is the critical uncertainty: FY2025 peak ($1.06B FCF) vs. FY2023 trough ($304M FCF) is a 3.5x swing — current price is cheap on peak, fair on trough
Book value of ~$42/share provides tangible asset backing; company trades at 1.86x book with ~30% of market cap in cash
Specialty egg mix now >50% with mostly fixed/cost-plus contracts — structural improvement to earnings stability, though not proven through a full cycle
DCF intrinsic value of $756 must be rejected as wildly optimistic — 12% growth from peak FCF is fantasy; conservative normalized value is $85-130/share range
Stock is at 52-week lows, 36% off highs, with institutional accumulation and insider board grants — some evidence of indiscriminate selling creating opportunity
Prepared foods strategy (Echo Lake, Creighton, Crapini) is credible but unproven at scale; 18-24 month ramp introduces meaningful execution risk

Red flags

DCF built on peak FCF with 12% perpetual growth — exactly the optimistic-forecast trap; intrinsic value is not $756, it is far lower on normalized basis
Q3 FY2026 EPS collapse of -90% YoY ($1.60 vs $10.38) reveals extreme commodity cyclicality — this is the true baseline risk, not the 2025 supercycle
Margin of safety thin to moderate on normalized FCF; if trough earnings of $200-300M persist, $80 offers limited downside protection (~$55-75 fair value range)
Prepared foods segment margin disclosure opacity: management does not break out segment margins, making it impossible to independently verify profitability claims
No explicit earnings guidance; 'normalized earnings power' framing is vague and not stress-testable — a Klarman red flag for transparency
Variable dividend (only $0.35/100 shares paid in soft quarter) limits income floor appeal; dividend is not a reliable downside anchor
Conventional egg pricing swung from $2.69 to $0.85 within a single quarter — structural pricing power is genuinely limited in the commodity segment

Peter Lynch — 🟡 watch · 58/100 · medium confidence

Cal-Maine is a classic Lynch cyclical — a simple, understandable business (largest U.S. egg producer) with a story you can explain in one sentence: they sell eggs, the most protein-dense food staple, at scale with a dominant market position. The PEG is extraordinarily low at 0.09, but this is a trap: the P/E of 3.12 is priced off a cyclical earnings peak (FY2025 net income $1.22B, EPS ~$25), not normalized earnings. Lynch's core rule is that for cyclicals, you buy when the P/E is HIGH (trough earnings) and sell when the P/E is LOW (peak earnings). The current 3.12x P/E flashes a warning, not a buy signal — Q3 FY2026 already showed EPS collapsing 90% YoY ($1.60 vs. $10.38). On CURRENT/normalized earnings the P/E is far higher. Street consensus is ~$0.58 Q4 EPS, annualizing to roughly $3-4/share forward, implying a normalized P/E of ~20-27x — not cheap for a cyclical. The balance sheet is superb: virtually zero long-term debt ($641K), $1.15B cash, current ratio 5.46, which Lynch loves. ROIC of 59% and ROE of 60% are extraordinary but reflect the peak cycle. The specialty egg mix shift (now 50.5% of sales) and prepared foods pivot (Echo Lake, Crapini, Creighton Brothers) are real strategic moves that could flatten the earnings cycle and justify a 'stalwart' or 'turnaround' re-rating — but prepared foods is only 9.5% of sales and integration is unproven. The diworsification concern is real: Echo Lake, Crapini, Fannie Foods JV, Creighton/Crystal Lake — four acquisitions in quick succession in adjacent but unfamiliar prepared foods territory, exactly the pattern Lynch warned about. The Van's Foods acquisition (May 2026) extends further into branded packaged foods — further from the core egg business. The 3-year revenue CAGR of 34% is spectacular but almost entirely avian flu-driven price inflation, not unit growth, so it's not a repeatable formula. This is a cyclical masquerading as a growth story at the peak of the cycle, now rolling over. Lynch would categorize this as a cyclical with turnaround/stalwart aspirations. The prepared foods story is intriguing but early. Wait for the cycle to bottom, normalized earnings to be visible, and prepared foods to demonstrate actual margin contribution before calling this a fast grower or stalwart.

Key points

Classic Lynch cyclical: simple egg business, one-sentence story, largest U.S. producer — passes the 'invest in what you understand' test with flying colors
Balance sheet is fortress-grade: $641K long-term debt, $1.15B cash, current ratio 5.46 — Lynch loves this; company can survive the trough and fund M&A internally
Specialty egg mix now 50.5% of shell egg sales with 88% under fixed/cost-plus contracts — if this structurally dampens earnings volatility, it could re-categorize the stock from pure cyclical toward stalwart
PEG of 0.09 is computed off peak earnings; for cyclicals, low P/E = sell signal not buy signal; normalized P/E likely 20-27x on ~$3-4/share forward EPS
Board expansion (10 members now), insider restricted stock grants, and superinvestor buying (Acquirer's Multiple, Feb 2026) are modestly supportive signals Lynch would note
Revenue CAGR of 34% over 3 years is entirely price-driven (avian flu + commodity spike), not unit/volume-driven — not the repeatable roll-out formula Lynch rewards

Red flags

Cyclical peak earnings trap: P/E 3.12x on FY2025 peak EPS of ~$25; Q3 FY2026 already shows 90% EPS collapse — buying at low P/E on peak cyclical earnings is a classic Lynch mistake to avoid
Diworsification risk: four acquisitions (Echo Lake, Crapini JV, Creighton/Crystal Lake, Van's Foods) into prepared foods in rapid succession — Lynch would flag this as the profitable company making pricey, potentially unrelated deals instead of sticking to core egg dominance
Earnings growth not durable or repeatable: the 3-year revenue/earnings surge was AI (avian influenza) driven, not unit expansion or a cloneable store/product roll-out
Prepared foods only 9.5% of sales with margins at trough — too early to re-categorize as a prepared foods growth story; integration track record unproven
No formal EPS guidance and segment margin opacity make it impossible to independently verify the normalized earnings power management references — Lynch hates opaque accounting
Conventional egg pricing crashed from $2.69 to $0.85/dozen in a single quarter — structural pricing power is minimal; commodity exposure remains the dominant earnings driver despite hybrid pricing contracts

Walter Schloss — 🟡 watch · 58/100 · medium confidence

Cal-Maine Foods presents a genuinely mixed picture through the Schloss value lens. On the positive side, the balance sheet is a fortress: virtually zero long-term debt ($641K — essentially nothing), current ratio of 5.46, stockholders' equity of $2.05B, and $1.15B in cash. Debt-to-equity of 0.0003 is as clean as it gets. The business is simple, asset-rich, and has been operating for decades — exactly the kind of company Schloss could read off the filings. The price is near its 52-week low (in fact, the data shows last close = 52w high at $80.23, but the fundamentals block separately shows a 52w high of $126.40, meaning the stock is ~36% below its recent peak), which is the kind of beaten-down, out-of-favor setup Schloss hunted. However, the price-to-book of 1.86x is above tangible book — not a deep discount. Schloss preferred to buy at or below book, ideally tangible book. At 1.86x book with $2.05B equity and 48.5M shares, implied book value per share is roughly $42.07, meaning the stock at $80.23 trades at a meaningful premium to book. That alone disqualifies this as a classic Schloss deep-value net-asset bargain. The earnings picture is also cyclically distorted: FY2024 net income was $1.22B (stellar), but Q3 FY2026 EPS collapsed 90% YoY — this is a volatile commodity business where book is the only stable anchor, and the book anchor doesn't provide a margin of safety at current prices. The DCF suggests massive theoretical upside ($756 intrinsic vs. $80 price), but Schloss explicitly avoided relying on earnings projections and DCF narratives — he wanted assets, not forecasts. The variable dividend policy (tied to earnings) is a yellow flag; Schloss preferred a consistent, durable dividend as a signal of balance sheet strength. Prepared foods expansion via acquisitions adds complexity and integration risk — Schloss avoided complexity. On the plus side: management/family ownership is historically significant for CALM (Adams family), the operating history is long and readable, and the balance sheet genuinely protects downside. But the 1.86x P/B premium, near-52w-high positioning (relative to the true 52w high of $126), and earnings-dependent thesis push this into watch territory rather than a clear Schloss buy.

Key points

Balance sheet is exceptional: debt-to-equity 0.0003, current ratio 5.46, $1.15B cash, virtually zero long-term debt — Schloss's ideal financial structure
Stock is ~36% below its 52-week high of $126.40 (fact base fundamentals block), consistent with beaten-down, out-of-favor setup Schloss preferred
Price-to-book of 1.86x — trades above tangible book (~$42/share implied); Schloss wanted at or below book for a true margin of safety in hard assets
Simple, long-operating-history business (egg production) readable from annual filings — exactly the kind of company Schloss understood
$2.05B in stockholders' equity vs. $438M in total liabilities — asset-heavy and conservatively financed with real tangible assets (plant, flock, working capital)
Earnings are violently cyclical (FY2024 net income $1.22B; Q3 FY2026 EPS down 90%) — book value is the only reliable anchor, and it doesn't support current price on Schloss terms
Variable dividend tied to earnings reduces reliability as a signal of durable balance sheet strength

Red flags

Price-to-book of 1.86x is above Schloss's comfort zone; no meaningful discount to net tangible assets — the primary Schloss margin of safety criterion is not met
Current price ($80.23) is near the 52-week high area relative to trough ($71.92 low), and significantly below the $126.40 prior peak — directionally acceptable but not at distressed levels
Prepared foods M&A (Echo Lake, Creighton Brothers, Crapini) adds balance sheet complexity, goodwill/intangibles risk, and integration uncertainty — Schloss avoided complexity
Commodity earnings volatility makes the earnings-based DCF ($756 intrinsic) unreliable as a Schloss anchor — he would not trust a forecast-dependent valuation
Variable/formula-based dividend ($0.35/share recent quarter) does not provide the consistent, predictable income signal Schloss used to validate balance sheet durability
No formal earnings guidance; reliance on 'normalized earnings power' narrative is exactly the kind of projections-dependent thesis Schloss distrusted

Michael Mauboussin — 🟡 watch · 58/100 · medium confidence

Cal-Maine presents a genuinely interesting expectations-investing puzzle. The headline numbers are stunning at the cycle peak (ROIC 59%, FCF margin 25%, P/E 3.1x, P/FCF 3.6x), but the key Mauboussin question is: what do these metrics reflect — durable franchise economics, or a commodity windfall that the market is correctly discounting as transitory? The answer is mostly the latter, with some real but modest structural improvement underway.

ROIC vs WACC: At 59% ROIC vs. ~7% WACC the spread appears massive, but this is peak-cycle distortion. In FY2021 (a lean year), ROIC was razor-thin. In FY2023 (a down year), net income was $278M on $2.3B revenue. The base rate for commodity food processors is ROIC barely above WACC through the cycle. The Q3 FY2026 earnings collapse (-90% YoY EPS) is the mean-reversion mechanism working in real time. Normalized ROIC is probably in the 15-25% range — still above WACC but the spread width is uncertain.

Moat Assessment — Narrow, trajectory mixed: (1) Scale economies: Real but limited. CALM is the largest U.S. shell egg producer (~20% market share), giving cost advantages in feed procurement, logistics, and fixed-cost absorption. This is a genuine but fragile barrier — avian flu can wipe out a flock and invert the cost advantage overnight. (2) Switching costs: Essentially none for conventional eggs — eggs are eggs to most consumers and retailers can switch suppliers. Specialty eggs carry slightly higher switching costs (supply chain certification, branding), but these are embryonic. (3) Network effects: Absent. (4) Intangibles: Brand is weak at the commodity shell egg level; slightly better for cage-free/specialty but no pricing power evidence that persists through cycles. The specialty mix shift (now 50.5% of shell egg sales) and prepared foods pivot (~9.5% of revenue) are genuine moat-building efforts, but they are early-stage and unproven at scale. Moat rating: Narrow, trajectory tentatively strengthening but not yet demonstrated in normalized margins.

Expectations embedded in the price: At $80.23, with trailing P/FCF of 3.6x and P/E of 3.1x, the market is emphatically NOT pricing in a durable franchise. It is pricing in significant mean-reversion of earnings. The DCF model's $756 intrinsic value is almost certainly wrong — it uses $1.06B base FCF (cycle-peak) and applies 12% perpetual growth, producing a nonsensically large number the model itself flags. The real question is what the normalized FCF looks like. If I anchor on FY2023 FCF ($304M) as a reasonable trough and average it with the peak, I get roughly $600-700M normalized FCF. At $80.23 with ~48.5M shares ($3.8B market cap, ~net cash $140M), the market is implying EV/normalized-FCF of roughly 6-7x — not cheap for a commodity processor, but not expensive either. The embedded expectations are roughly: commodity egg prices remain depressed (consistent with AI recovery), specialty margins hold, prepared foods contributes modestly. This is a reasonable base case — neither obviously wrong nor clearly too pessimistic.

Skill vs. luck decomposition: The FY2024-peak earnings were primarily luck (avian flu supply shock driving egg prices to extraordinary levels). Management's response — accelerating specialty mix, acquiring Echo Lake/Creighton Brothers, building prepared foods — reflects genuine skill in capital allocation during a windfall. The balance sheet ($1.15B cash, effectively zero LTD) and capital allocation record ($384M dividends + $299M M&A + $150M buybacks + $117M CapEx from ~$1B deployed) are disciplined. But the underlying earnings power remains hostage to avian flu outcomes and commodity grain prices in ways that no management skill fully mitigates.

Distribution of outcomes: Bull (25% probability): Specialty mix reaches 60-65%, prepared foods scales to 15-20% of revenue at 19-20% margins, AI stays contained, normalized ROIC holds 25-30% — stock worth $100-130. Base (50% probability): Specialty stabilizes at 50%, prepared foods ramp is lumpy, normalized earnings ~$3-5/share, stock fairly valued at $60-90. Bear (25% probability): AI resurgence, feed cost spike, specialty pricing pressure, prepared foods integration stumbles — normalized EPS <$2, stock $40-55. The distribution is roughly symmetric around current price with modest upside optionality from the specialty/prepared-foods optionality. Fat tails are on the downside (commodity shock) not upside.

What would change my view: Bullish revision triggers — evidence that specialty egg margins are genuinely sticky through a full commodity down-cycle; prepared foods hitting 19%+ gross margins by Q4 FY2026 on schedule; avian flu resolution. Bearish revision — ROIC compression on normalized basis toward 10-15%; M&A integration failures showing up in segment margin disclosure; conventional egg price recovery driving retail backlash on specialty premiums.

Key points

ROIC of 59% is peak-cycle, not structural; normalized ROIC likely 15-25% — above WACC but uncertainty is high and mean-reversion is the base rate for commodity food processors
Moat is Narrow: real scale economies in procurement/logistics as largest U.S. egg producer, but near-zero switching costs for conventional eggs and embryonic specialty/brand intangibles not yet proven through a full cycle
Specialty mix shift to 50.5% of shell egg sales and prepared foods at 9.5% of revenue are genuine moat-building vectors, but both are early-stage with undemonstrated normalized margins
Expectations embedded at $80 are roughly neutral — market is discounting cycle normalization, not pricing in franchise durability; DCF model's $756 intrinsic value is fatally flawed by peak-FCF base assumption
Capital allocation discipline is a genuine skill signal: $1B deployed across dividends, M&A, buybacks, and CapEx from windfall earnings; balance sheet ($1.15B cash, near-zero debt) provides meaningful optionality
Q3 FY2026 EPS -90% YoY demonstrates commodity earnings volatility that overwhelms any near-term ROIC spread analysis — outside view base rate argues for significant mean-reversion

Red flags

DCF intrinsic value of $756 uses peak FCF as base with 12% perpetual growth — this is egregious FCF normalization failure that inflates intrinsic value by 5-10x; the caveat in the model is too mild
ROIC of 59% is almost entirely cycle-driven (avian flu supply shock); treating it as evidence of franchise quality would be a classic luck-vs-skill error
Moat has no network effect, minimal switching costs for conventional eggs (>50% of volume), and brand intangibles are unproven at premium pricing through down-cycle conditions
Prepared foods recovery trajectory (19-20% margins by FY2027-28) is management guidance with no segment-level margin disclosure to verify progress — opacity is a yellow flag for expectations analysis
Acquisition track record (Echo Lake, Creighton, Crapini) is too recent to assess ROIC on deployed capital — M&A execution risk is real at scale
Variable dividend policy tied to earnings means dividend income is unreliable in trough years, limiting the income-floor valuation support that might otherwise anchor downside

Charlie Munger — 🟡 watch · 55/100 · medium confidence

Cal-Maine is an understandable business — the unit economics of shell egg production are simple enough to explain in a paragraph — but it fails the most critical Munger test: a durable, identifiable moat. Eggs are a commodity. Conventional pricing collapsed from $2.69 to $0.85 within a single quarter in Q3 FY2026, producing a 90% EPS decline year-over-year. That is the signature of a business with no pricing power over its core product. The specialty egg pivot (now >50% of shell egg mix) and prepared foods push are genuine strategic improvements, but they are not yet proven moat-builders — specialty pricing stability depends largely on fixed/cost-plus contracts (a contractual arrangement, not a durable competitive advantage), and prepared foods represent only ~9.5% of net sales with margins currently in a self-described trough and recovery speculative over 18–24 months. Where Munger sees genuine quality: ROIC of 59%, ROE of 60%, virtually zero debt ($641K long-term debt), a fortress balance sheet ($1.15B cash), FCF conversion that is real and substantial ($1.06B FCF on $1.22B net income — earnings are not fictional), and management that appears honest, rational, and owner-minded (disciplined capital allocation across dividends, buybacks, and strategic M&A; no serial dilution; hybrid pricing designed to reduce volatility rather than chase upside). The variable dividend policy tied to earnings is actually Munger-compatible — no pretending to earnings stability that doesn't exist. However, the business's intrinsic earnings power is deeply cyclical: FY2020 net income was $2M; FY2022 was $758M; FY2024 was $1.22B. This is not the stable, predictable compounding machine Munger prizes. The DCF intrinsic value of $756/share vs. $80 current price is almost certainly an artifact of projecting peak-cycle FCF at 12% growth — a number I would invert immediately: what is the normalized, mid-cycle FCF? The history (2020: negative FCF; 2021: $54M; 2023: $304M) suggests $300–500M is a more realistic mid-cycle figure, implying the apparent cheapness is partly illusory. At P/B of 1.86x on a highly cyclical, commodity-exposed asset base, this is not screaming undervaluation on a quality-adjusted basis. The Van's Foods acquisition (prepared foods expansion) and board additions are neutral signals — not alarming, but not evidence of a Munger-grade capital allocation track record either. The inversion test: how does this go to zero? Persistent avian flu + structural egg oversupply + feed cost spike + prepared foods integration failure = multi-year earnings drought. The balance sheet survives this, so permanent capital impairment is unlikely — but permanent underperformance of intrinsic value growth is the more realistic risk. This is a good-but-not-great business at what looks like a fair price, not a great business at a fair price. Munger would watch it, not buy it at scale.

Key points

ROIC of 59% and ROE of 60% are exceptional numbers, but they reflect a commodity supercycle peak — not sustained moat-driven returns; FY2020 ROE was near zero
Balance sheet is genuinely fortress-grade: $641K long-term debt, $1.15B cash, current ratio 5.46 — passes the 'survive a downturn' test with ease
FCF conversion is clean: $1.06B FCF vs. $1.22B net income; earnings are real, not accounting fiction
Specialty egg mix >50% and fixed/cost-plus contracts on ~88% of specialty pricing represent genuine risk reduction, but contractual protection ≠ durable competitive moat
Management capital allocation is rational: ~$384M dividends, $150M buybacks, $299M strategic M&A, $117M CapEx over 12 months — no empire-building
Unit economics are simple and understandable — this sits comfortably within the circle of competence for an investor willing to think about egg industry dynamics
Variable dividend policy is honest about earnings cyclicality — not a Munger red flag, actually marks management as candid

Red flags

No durable moat in conventional eggs: Q3 FY2026 showed $2.69 to $0.85 pricing collapse within one quarter — textbook commodity price-taker
Earnings cyclicality is extreme: net income ranged from $2M (FY2020) to $1.22B (FY2024); this is not a compounder, it is a cyclical
DCF intrinsic value of $756/share almost certainly projects peak-cycle FCF at an unrealistic growth rate — normalized mid-cycle FCF is likely $300–500M, making apparent cheapness partly illusory
Prepared foods (the higher-quality segment) is only 9.5% of sales, margins are currently depressed, and recovery is speculative over 18–24 months with unproven integration track record
Specialty egg 'moat' is contractual, not structural — fixed/cost-plus pricing can be renegotiated; no brand, switching cost, or network effect protects these arrangements permanently
Segment margin opacity: CALM does not break out margins by specialty vs. conventional vs. prepared foods — limits ability to verify management's profitability claims independently
Recent M&A pace (Echo Lake, Creighton Brothers, Crystal Lake, Crapini, Van's Foods) is accelerating; integration risk and return-on-acquisition capital unproven at this scale

Chuck Akre — 🟡 watch · 52/100 · medium confidence

Cal-Maine is an intriguing but ultimately problematic fit for the Akre three-legged stool. Leg one (extraordinary business) is the most contested: the current financial metrics are spectacular on the surface — ROIC of 59%, ROE of 60%, FCF margin of 25%, virtually zero debt — but these are peak-cycle numbers inflated by the 2024-2025 avian influenza-driven egg price supercycle. The history makes this painfully clear: in 2020, FCF was negative (-$69M); in 2021, ROIC was minimal; in 2023, a 'normal' year, revenue fell 26% and FCF was only $304M. The business is fundamentally a commodity price-taker on conventional shell eggs, where a $2.69 to $0.85 per-dozen price swing in a single quarter caused EPS to collapse 90% YoY in Q3 FY2026. That is not the profile of a franchise with durable pricing power. Leg two (skilled, honest management) is more favorable: the Adams family-controlled company has allocated capital intelligently — diversifying into specialty eggs (now >50% of mix) and prepared foods (Echo Lake, Creighton Brothers), maintaining a fortress balance sheet ($1.15B cash, effectively zero long-term debt per current filings), and using a variable dividend policy that is honest about earnings cyclicality rather than promising an unsustainable fixed payout. Communication appears candid. However, the prepared foods acquisitions are unproven at scale and integration risk is real. Leg three (reinvestment runway) is the most uncertain: the specialty egg pivot and prepared foods build-out represent genuine reinvestment opportunities, and management is deploying capital ($299M in acquisitions, $117M capex in recent 12 months). But the ultimate market — commodity eggs — is not a large, underpenetrated growth market. It is mature, and specialty eggs face rising competition. The DCF's intrinsic value of $756/share (vs. $80 current price) appears wildly inflated — it uses peak-cycle FCF of $1.06B as the base and compounds it at 12% for five years, which is almost certainly not the normalized earnings power of this business. Using the 2023 'trough' FCF of $304M as a more representative normalized base cuts the intrinsic value by roughly two-thirds, suggesting a more realistic intrinsic value in the $200-250 range — still well above current price, but the margin of safety relative to normalized earnings is not as dramatic as the headline DCF implies. At $80/share and P/FCF of 3.6x on peak earnings, the stock is cheap on peak, but the Akre framework requires durable, repeatable returns — not cyclical peak returns. The price-to-book of 1.86x and P/S of 0.89x are genuinely cheap metrics for a business with strong assets. The 3-year revenue CAGR of 34% is largely avian flu-driven, not organic franchise expansion. Net-net: two of three legs are partially intact (management quality decent, some reinvestment avenue exists), but the core commodity economics undermine the 'extraordinary business' criterion and the reinvestment runway is narrow relative to the market size. This is a watch, not a pass.

Key points

Peak-cycle ROIC/ROE of 59-60% is spectacular but not durable — the commodity egg business has produced near-zero or negative FCF in soft years (2020: -$69M FCF, 2023: $304M vs $1.06B peak)
Management quality is above average for the sector: virtually debt-free balance sheet, honest variable dividend policy, credible specialty egg pivot (now >50% of mix), and transparent acknowledgment of cyclical headwinds
Specialty egg mix shift to >50% and prepared foods expansion (9.5% of sales) represent genuine reinvestment avenues, but the prepared foods margin recovery (19-20% target) is speculative over 18-24 months
DCF intrinsic value of $756/share is misleading — built on peak FCF base; normalized FCF closer to $300-400M implies intrinsic value far lower, though still above current $80 price
At $80/share the stock is genuinely cheap on any reasonable normalized earnings metric (P/B 1.86x, P/S 0.89x), offering some margin of safety, but cheapness alone is not the Akre criterion
Board governance improving: addition of independent directors, variable dividend honesty, and capital allocation track record (M&A, buybacks, capex) shows disciplined stewardship

Red flags

Core conventional egg business is a textbook commodity price-taker — a single quarter saw egg prices fall from $2.69 to $0.85/dozen causing 90% EPS collapse, fundamentally incompatible with 'extraordinary business' criterion
Peak-cycle FCF of $1.06B used as DCF base is almost certainly not normalized earnings power; 2020-2021 history shows the business can generate near-zero or negative FCF in normal/soft markets
No durable moat: commodity eggs have no brand differentiation, switching costs, or network effects; specialty eggs face rising competitive pressure and promotional activity per management commentary
Prepared foods acquisitions (Echo Lake, Creighton Brothers, Crapini) are unproven at scale; integration risk and segment margin opacity make it impossible to verify management's 19-20% target claims independently
Reinvestment runway is structurally limited — mature egg market with population-level consumption growth; incremental returns on prepared foods capex unclear and not yet demonstrated
Revenue CAGR of 34% is largely avian flu-driven price inflation, not franchise expansion — the compounding machine metaphor breaks down when the driver is an exogenous disease cycle

Terry Smith (Fundsmith) — 🔴 avoid · 32/100 · high confidence

Cal-Maine Foods is a commodity egg producer — precisely the kind of capital-intensive, cyclically volatile, low-moat business Fundsmith avoids. While the most recent fiscal year (FY2025 ending May 2025) posted spectacular headline numbers driven by avian flu-induced egg price spikes (ROIC 59%, operating margin 36%, FCF $1.06B), the five-year history reveals the underlying reality: in FY2020 net income was $2M on $1.35B revenue; in FY2023 (post-spike normalization) net income collapsed to $278M and FCF to $304M; and Q3 FY2026 saw EPS fall 90% YoY to $1.60. This is not a high-quality compounder — it is a price-taker in a commodity market whose earnings are almost entirely at the mercy of wholesale shell egg prices set by avian flu epidemics, feed costs, and supply/demand imbalances. The 'moat' is essentially non-existent: eggs are fungible commodities, brand differentiation is minimal at the conventional level, and specialty eggs (now 50% of mix) face growing competition. ROCE across the full cycle — not the AI-spike year — normalises far below the 20%+ threshold Smith requires; FY2021 net margin was 7.5% and FY2020 was essentially zero. The DCF intrinsic value of $756/share is a mathematical artefact of plugging peak FCF ($1.06B) into a perpetuity — the caveat in the fact base correctly flags this as requiring FCF normalisation. Normalised FCF is likely $200–400M, implying a very different valuation. On the positive side: the balance sheet is genuinely fortress-like (debt/equity 0.0003, $1.15B cash, current ratio 5.46), and cash conversion has been excellent in peak years (FCF closely tracks net income). Capital intensity is moderate (capex $161M vs. OCF $1.22B in FY2025). But these virtues cannot overcome the fundamental disqualifier: this is a commodity business with no durable pricing power, structurally volatile returns, and an earnings history that swings from near-zero to extraordinary based on exogenous supply shocks. The ongoing prepared-foods pivot is acquisitive (Echo Lake, Creighton Brothers, Crapini — serial M&A) with unproven margin delivery and segment opacity. Smith explicitly distrusts acquisitive diversification strategies executed under margin pressure. The variable dividend (paying $0.35/100 shares in soft quarters) confirms the lack of earnings predictability Smith demands.

Key points

ROIC of 59% and operating margin of 36% in FY2025 are spike-year anomalies driven by avian flu supply disruption, not sustainable competitive advantage — FY2020 net income was $2M, FY2023 net income $278M
Full-cycle ROCE normalises well below Fundsmith's 20%+ threshold; the business structurally earns near cost-of-capital or below in normalised egg price environments
No genuine economic moat: eggs are a commodity, Cal-Maine is a price-taker, and the specialty/cage-free segment faces rising competition and contract proliferation
Balance sheet is exceptional (near-zero debt, $1.15B cash, 5.46 current ratio) — the one genuine quality attribute that passes the Smith screen
Cash conversion is strong in peak years (FCF $1.06B vs. net income $1.22B in FY2025), but this tracks commodity price cycles rather than durable earnings quality
Serial acquisitive M&A (Echo Lake, Creighton Brothers, Crystal Lake, Crapini JV) is a Smith red flag; prepared foods segment margins opaque and recovery speculative over 18–24 months
DCF intrinsic value of $756/share is misleading — built on peak FCF; normalised FCF of ~$200–400M would imply intrinsic value far closer to current market price

Red flags

Commodity business with no pricing power — conventional egg prices swung from $2.69 to $0.85 in a single quarter (Q3 FY2026)
Earnings collapsed 90% YoY in Q3 FY2026 (EPS $1.60 vs. $10.38); this is the norm, not the exception, in non-AI-spike years
Serial acquisitions (Echo Lake Foods, Creighton Brothers, Crystal Lake, Crapini JV) with no segment-level margin disclosure — classic Smith disqualifier
Prepared foods pivot is acquisitive, early-stage, and unproven; management itself guides recovery only by FY2027–2028
No formal earnings guidance; management relies on 'normalised earnings power' framing that obscures genuine earnings volatility
Variable dividend tied to earnings provides no income stability — retail investors already questioning dividend adequacy
Five-year net income range: $2M to $1.22B — the definition of a cyclical commodity business, antithetical to Smith's predictability requirement

Stanley Druckenmiller — 🔴 avoid · 28/100 · high confidence

CALM is a textbook case of what I explicitly avoid: a backward-looking 'cheap' trap with decelerating fundamentals and a tape that has rolled over hard from the highs. The forward earnings picture is the opposite of an inflection upward — Q3 FY2026 EPS collapsed 90% YoY, revenue fell 53%, and the company has deliberately avoided giving forward guidance, leaving the 'normalized earnings power' thesis entirely speculative. The second derivative is pointing sharply DOWN. The stock sits at $80.23 — trading at its 52-week low, having fallen from $126.40 — nearly 37% off the highs with zero sign of a price inflection. The tape flatly disagrees with any bullish narrative. This is a commodity egg producer where pricing is driven by avian flu cycles and feed costs — there is no identifiable monetary or policy catalyst. The Fed tailwind question is largely irrelevant here since CALM's earnings are driven by egg prices and bird flu, not liquidity cycles. The DCF intrinsic value of $756/share sounds extraordinary but is a mechanical artifact of using peak-cycle FCF of $1.06B as the base — management themselves just printed a quarter where earnings were down 90%. If I normalize FCF to something resembling a mid-cycle number, the valuation story evaporates. There is no 'why now' catalyst I can identify: specialty mix shift is real but slow-moving and already known to the market, prepared foods recovery is 18-24 months away by management's own admission, and competitive pricing pressure is rising. The variable dividend adds no anchor. The one structural positive — the fortress balance sheet with ~$1.15B cash and zero debt — prevents this from being a disaster but does nothing to create the asymmetric, catalyst-driven setup I require. I cannot size into a stock whose tape is making new lows with forward estimates being revised down and no clear inflection catalyst within 6-12 months.

Key points

EPS collapsed 90% YoY in Q3 FY2026; revenue -53%; forward direction is DOWN not inflecting
Stock trading at 52-week low ($80.23), down 37% from $126.40 high — tape confirms fundamental deterioration
No forward guidance issued; 'normalized earnings power' is management's own vague framing, not a catalyst
DCF $756 intrinsic value built on peak-cycle FCF ($1.06B) that just demonstrated 90% crash in one quarter
Prepared foods recovery targeted for FY2027-2028 — too distant and speculative for a momentum/macro setup
Balance sheet fortress ($1.15B cash, zero debt) is the one genuine positive but creates no asymmetric payoff

Red flags

Tape breaking down to 52-week low while bull narrative persists — primary Druckenmiller disqualifier
Decelerating second derivative: from peak earnings cycle to 90% YoY EPS decline in a single quarter
No defined invalidation point — management's 'normalized earnings' framing has no testable near-term milestone
Commodity egg pricing driven by AI (avian influenza) and feed cost cycles, not policy/liquidity — no Fed tailwind lever
Forward estimates ($0.53-0.58 Q4 EPS) are tiny vs. peak; entire valuation rests on mean reversion with no timing clarity
Backward-looking cheap trap: P/E of 3.12x and P/FCF of 3.57x reflect LAST YEAR'S peak earnings, not current trajectory

Philip Fisher — abstained

Cal-Maine Foods is a commodity egg producer. Its economics are driven by avian flu cycles, feed costs, and wholesale egg pricing — not by R&D, product innovation, or an expanding technological moat. While management is executing a credible specialty-egg and prepared-foods mix shift, this is a portfolio-repositioning story within a commodity agricultural business, not the kind of durable, organically compounding product franchise that Fisher's scuttlebutt method is designed to evaluate. Revenue swings from $1.3B (2020) to $4.3B (2024) reflect commodity price cycles — the 33.8% 3-year CAGR is almost entirely price-driven (avian flu supply shock), not volume or product innovation led. Q3 FY2026 revenue collapsed 53% YoY in a single quarter, which is characteristic of commodity exposure, not franchise pricing power. There is no meaningful R&D line, no technology pipeline, no defensible product moat that Fisher's framework rewards. Applying a Fisher growth lens here would force an irrelevant verdict.

Key points

Revenue CAGR of 33.8% is commodity-price-cycle driven, not organic product/market expansion — confirmed by Q3 FY2026 -53% revenue collapse
No R&D spend visible in filings; innovation is absent as a driver — the core Fisher criterion is simply not present
Specialty egg mix shift (now 50.5%) and prepared foods (9.5% of sales) represent operational repositioning, not a product innovation pipeline
Business economics are dominated by wholesale egg prices, avian flu supply disruptions, and feed costs — all exogenous commodity variables
Fisher's method requires scuttlebutt validation of a franchise; no franchise durability exists in a commodity where pricing power collapsed from $2.69 to $0.85 in one quarter

Red flags

Growth is episodic and price-driven, not earned through R&D or new market creation — the core Fisher disqualifier
No R&D investment means no pipeline, no compounding product advantage, and no basis for a Fisher-style long-term hold thesis
Margin volatility is extreme: operating margin swings between near-zero and 36% purely on commodity cycles, not competitive positioning
Acquisitions (Echo Lake, Creighton Brothers, Crapini) are driving prepared foods growth — bought rather than earned organically
EPS collapsed 89.8% YoY in Q3 FY2026 — antithetical to the sustained, above-average compounding that Fisher demands

Fact base appendix

Price

last_close: 80.23
as_of: 2026-06-27
high_52w: 80.23
low_52w: 80.23
pct_below_52w_high: 0.0

Fundamentals

last_price: 80.23
market_cap: 3801023770
fifty_two_week_high: 126.4
fifty_two_week_low: 71.92
beta: 0.22171155
currency: USD
exchange: NASDAQ NMS - GLOBAL MARKET
sector: Food Products
industry: Food Products
price_source: finnhub
bars: 1
entity: Cal-Maine Foods, Inc.
fiscal_year: 2024
revenue: 4261885000
revenue_period: 2025-05-31
net_income: 1220048000
net_income_period: 2025-05-31
operating_income: 1536539000
operating_income_period: 2025-05-31
operating_cash_flow: 1224734000
operating_cash_flow_period: 2025-05-31
capex: 161255000
capex_period: 2025-05-31
total_assets: 2490099000
total_assets_period: 2024-11-30
total_liabilities: 438616000
total_liabilities_period: 2024-11-30
current_assets: 1424595000
current_assets_period: 2024-11-30
current_liabilities: 260751000
current_liabilities_period: 2024-11-30
stockholders_equity: 2045367000
stockholders_equity_period: 2024-11-30
cash_and_equivalents: 140296000
cash_and_equivalents_period: 2024-11-30
long_term_debt: 641000
long_term_debt_period: 2019-06-01
shares_outstanding: 48497477
operating_margin: 0.3605
net_margin: 0.2863
roe: 0.5965
debt_to_equity: 0.0003
current_ratio: 5.4634
roic: 0.5933
free_cash_flow: 1063479000
fcf_margin: 0.2495
pe_ratio: 3.12
price_to_fcf: 3.57
price_to_sales: 0.89
revenue_cagr: 0.3385
revenue_cagr_years: 3
fundamentals_source: edgar_companyfacts
price_to_book: 1.86
earnings_yield: 0.4197
peg: 0.09

Filings reviewed

8-K (2026-06-23) https://www.sec.gov/Archives/edgar/data/16160/000156276226000074/calm-20260623_8K.htm
8-K (2026-04-01) https://www.sec.gov/Archives/edgar/data/16160/000156276226000048/8k20260331.htm
10-Q (2026-04-01) https://www.sec.gov/Archives/edgar/data/16160/000156276226000046/calm-20260228.htm
10-Q (2026-01-07) https://www.sec.gov/Archives/edgar/data/16160/000156276226000004/calm-20251129.htm
10-K (2025-07-22) https://www.sec.gov/Archives/edgar/data/16160/000156276225000170/calm2025053110K.htm
10-K (2024-07-23) https://www.sec.gov/Archives/edgar/data/16160/000156276224000177/calm2024060110K.htm

Other sources

[news] Cal-Maine Foods: One-Stop Shop For All Things Egg (Pre-Earnings) - Seeking Alpha
[news] Form 4 Cal-Maine Foods Inc For: 24 June By Investing.com - Investing.com Canada
[news] CAL-MAINE FOODS (NASDAQ: CALM) director receives 1,301-share restricted stock grant - Stock Titan
[news] Cal-Maine Foods (CALM) director receives 1,301-share restricted stock grant - Stock Titan
[news] Cal-Maine Foods (CALM) outside director Michael Highfield files Form 3 - Stock Titan
[news] Haley Fisackerly files initial Form 3 as Cal-Maine Foods (CALM) director - Stock Titan
[news] Energizer, Cal-Maine, and B&G Foods Shares Are Soaring, What You Need To Know - Yahoo Finance
[news] Cal-Maine adds two independent directors as board grows to 10 - Stock Titan
[news] Price to sales forward of Cal-Maine Foods, Inc. – NASDAQ:CALM - TradingView
[news] Cal-Maine Foods, Inc. (CALM): A Deep Value Commodity Business - The Acquirer's Multiple
[news] Cal-Maine Foods Expands Prepared Foods Business with Van’s Foods Acquisition - Yahoo Finance
[news] Is Cal-Maine Foods, Inc. (CALM) A Good Stock To Buy? - Yahoo Finance
[news] Is Cal-Maine Foods, Inc. (CALM) A Good Stock To Buy Now? - Yahoo Finance
[news] Top Superinvestors Are Buying Cal-Maine Foods Inc. (CALM) - The Acquirer's Multiple
[news] Cal-Maine Foods, Inc. Actuals & Estimates (NASDAQ:CALM) - TradingView
[discussion] Wall St is expecting 0.58 EPS for $CALM Q4 [Reporting 07/28 BMO] http://www.estimize.com/intro/calm?
[discussion] @rsmracks $eqnR $calM $EXK Colonel Douglas McGreggor says buy energy miners fertilizer and food.
[discussion] $CALM This stock appears to move on fuel prices. If prices are up, it goes down. If prices are dow
[discussion] $CALM
[discussion] Wall St is expecting 0.53 EPS for $CALM Q4 [Reporting 07/28 BMO] http://www.estimize.com/intro/calm?
[discussion] [Bullish] $CALM super
[discussion] [Bullish] $CALM I'm in here. Not expecting any more blockbuster years, but their balance sheet i
[discussion] [Bullish] $CALM few more
[discussion] $CALM $CALM impact map: a new $18M fund bet puts Cal-Maine back on the watchlist. Direct read is ins
[discussion] [Bullish] $CALM
[discussion] Wall St is expecting 0.58 EPS for $CALM Q4 [Reporting 07/28 BMO] http://www.estimize.com/intro/calm?
[discussion] @rsmracks $cpB I bought a position just for fun of it. CAG at 13.2 a add. $calM is another as USA
[discussion] $CALM If it's a great divi stock why did it pay only $35 per 100 shares?
[discussion] $CALM Man I miss when dividend stocks moved up when the rest of the market went down.
[earnings_call] Cal-Maine Foods Q3 2026 Earnings Call | EPS Beats Estimates as Specialty Egg Sales Soar

Generated 2026-07-17T19:33:31 · est. cost $1.49

What each investor thinks

Valuation Referee (Damodaran-style) Referee

pass · 82

Joel Greenblatt Value

pass · 82

AI & Disruption Referee (Christensen-style) Referee

pass · 82

Benjamin Graham Value

pass · 78

Bruce Greenwald Value

pass · 78

Forensic Short-Seller (Chanos/Einhorn-style) Referee

pass · 78

Ray Dalio Risk

pass · 74

Howard Marks Risk

pass · 72

Warren Buffett Quality

watch · 58

Seth Klarman Value

watch · 58

Peter Lynch Growth

watch · 58

Walter Schloss Value

watch · 58

Michael Mauboussin Quality

watch · 58

Charlie Munger Quality

watch · 55

Chuck Akre Quality

watch · 52

Terry Smith (Fundsmith) Quality

avoid · 32

Stanley Druckenmiller Risk

avoid · 28

Want this on a name you own?Send a ticker; we convene the full council on it.

Request Analysis →

Cal-Maine Foods Inc

CAL-MAINE FOODS INC (CALM) — Council Assessment

🟡 WATCH · Score 63/100 · medium confidence

360 narrative — news & sentiment digest

CALM — Cal-Maine Foods Q3 FY2026 Briefing

Management Commentary (Earnings Call)

Recent Developments

Bull Narrative

Bear Narrative

Retail Sentiment

Caveats

Summary for Investment Council

Bull case

Bear case

Dissent — where the council disagrees

Key risks

Catalysts

DCF valuation (finance-expert model)

Short-sell evaluation

Council scorecard

Member reasoning

Valuation Referee (Damodaran-style) — 🟢 pass · 82/100 · medium confidence

Joel Greenblatt — 🟢 pass · 82/100 · high confidence

AI & Disruption Referee (Christensen-style) — 🟢 pass · 82/100 · high confidence

Benjamin Graham — 🟢 pass · 78/100 · medium confidence

Bruce Greenwald — 🟢 pass · 78/100 · medium confidence

Forensic Short-Seller (Chanos/Einhorn-style) — 🟢 pass · 78/100 · medium confidence

Ray Dalio — 🟢 pass · 74/100 · medium confidence

Howard Marks — 🟢 pass · 72/100 · medium confidence

Warren Buffett — 🟡 watch · 58/100 · medium confidence

Seth Klarman — 🟡 watch · 58/100 · medium confidence

Peter Lynch — 🟡 watch · 58/100 · medium confidence

Walter Schloss — 🟡 watch · 58/100 · medium confidence

Michael Mauboussin — 🟡 watch · 58/100 · medium confidence

Charlie Munger — 🟡 watch · 55/100 · medium confidence

Chuck Akre — 🟡 watch · 52/100 · medium confidence

Terry Smith (Fundsmith) — 🔴 avoid · 32/100 · high confidence

Stanley Druckenmiller — 🔴 avoid · 28/100 · high confidence

Philip Fisher — abstained

Fact base appendix

Valuation Referee (Damodaran-style) Referee

Joel Greenblatt Value

AI & Disruption Referee (Christensen-style) Referee

Benjamin Graham Value

Bruce Greenwald Value

Forensic Short-Seller (Chanos/Einhorn-style) Referee

Ray Dalio Risk

Howard Marks Risk

Warren Buffett Quality

Seth Klarman Value

Peter Lynch Growth

Walter Schloss Value

Michael Mauboussin Quality

Charlie Munger Quality

Chuck Akre Quality

Terry Smith (Fundsmith) Quality

Stanley Druckenmiller Risk